−Removed: We are a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system, or CNS, disorders with limited or no approved treatment options.
−Removed: Our vision is to finally fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with rare monogenic CNS diseases.
−Removed: The field of genetic medicine is rapidly expanding and we believe we have a differentiated approach to developing treatments for rare, monogenic CNS disorders that enables us to select and advance product candidates with a higher probability of technical and regulatory success.
+Added: We are a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system, or CNS, disorders with limited or no approved treatment options.
+Added: Our vision is to finally fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases.
+Added: The field of genetic medicine is rapidly expanding and we believe we have a differentiated approach to developing treatments for CNS disorders that enables us to select and advance product candidates with a higher probability of technical and regulatory success.
We have entered into a strategic research collaboration with the Trustees of the University of Pennsylvania’s, or Penn’s, Gene Therapy Program, or GTP , headed by Dr.
1 unchanged sentence
We also leverage our close working relationship with Penn’s Orphan Disease Center, or ODC, to develop historical and prospective comparable natural history patient profiles for comparison to participants in interventional trials.
−Removed: Through this collaboration we have assembled a deep portfolio of genetic medicine product candidates, including our three lead product candidates, all of which we retain global rights to:
+Added: Through this collaboration we have assembled a deep portfolio of genetic medicine product candidates, for which we retain global rights, including our three clinical product candidates:
PBGM01 for the treatment of GM1 gangliosidosis, or GM1 , PBFT02 for the treatment of frontotemporal dementia, or FTD, and PBKR03 for the treatment of Krabbe disease.
−Removed: We currently have active INDs for our three lead programs in the United States, and clinical trial authorizations, or CTAs, for our Imagine-1 Trial for PBGM01 from the United Kingdom’s Medicines Healthcare Products Regulatory Agency, or MHRA, and Health Canada.
−Removed: We expect to initiate patient enrollment for Phase 1/2 trials for GM1 in the first quarter of 2021, for FTD in the first half of 2021 and for Krabbe disease in the first half of 2021.
−Removed: We will also continue to explore entering into new collaborations to build our pipeline.
−Removed: Our research collaboration with GTP provides us with access to one of the premier research institutions in the world for the discovery and preclinical development of genetic medicine product candidates and exclusive rights to certain rare, monogenic CNS disorders.
−Removed: As part of this collaboration, we have exclusive rights to all discovery work and IND-enabling research for up to 17 rare, monogenic CNS indications that we select.
−Removed: In addition to our three lead product candidates, we have four ongoing research programs and an option to license ten additional programs from GTP.
−Removed: Further, we have exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for Passage Bio products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation.
−Removed: We have global commercial rights to all of our product candidates and believe that our approach to developing therapies for rare, life-threatening diseases that are currently underserved presents an opportunity to efficiently advance our product candidates through clinical development, regulatory approval and ultimately to commercialization.
+Added: We have six programs in the research stage:
+Added: PBML04 for metachromatic leukodystrophy, or MLD, PBAL05 for amyotrophic lateral sclerosis, or ALS, PBCM06 for Charcot-Marie-Tooth Type 2A, or CMT2A, and unnamed programs for Canavan disease, Parkinson’s disease and Huntington’s disease.
+Added: We also have exploratory research programs for Alzheimer’s disease, or AD, and Temporal Lobe Epilepsy, or TLE.
We founded Passage Bio with the intent to build a differentiated CNS genetic medicines company delivering transformative therapies to patients by combining our team’s experience in rare and neurological disease development, manufacturing and commercialization with the pioneering research expertise of GTP in gene therapy.
6 unchanged sentences
We are focused on developing and commercializing disease-modifying therapies that can have a transformative impact on patients’ lives.
−Removed: Utilizing our rigorous selection process, we have assembled a deep portfolio of product
−Removed: candidates for rare, monogenic CNS disorders.
+Added: Utilizing our rigorous selection process, we have assembled a deep portfolio of product candidates for rare, monogenic CNS disorders.
Our first product candidate, PBGM01, utilizes a next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase, or β-gal, for GM1.
2 unchanged sentences
There are currently no approved disease-modifying therapies for these diseases.
−Removed: We believe our lead product candidates have the potential to provide patients with significantly improved outcomes, given our chosen route of intra cisterna magna, or ICM, administration, which is an injection at the craniocervical junction, our target choice of secreted proteins that leverage the cross-correction mechanism, thereby reducing transduction requirements and our capsid and transgene selection process which allows us to choose vectors that are fit-for-purpose for specific indications.
−Removed: We also have four programs in the research stage:
−Removed: PBML04 for metachromatic leukodystrophy, or MLD, PBAL05 for amyotrophic lateral sclerosis, or ALS, PBCM06 for Charcot-Marie-Tooth Type 2A, or CMT2A, and one program for an undisclosed target .
−Removed: PBML04 is targeting MLD patients who have mutations in the ARSA gene, PBAL05 is targeting ALS patients who have a gain-of-function mutation in the C9orf72 gene, PBCM06 is targeting CMT2A patients who have a mutation in the MFN2 gene and our undisclosed program is targeting an adult CNS indication.
−Removed: We also have an option to license ten additional programs from Penn in rare, monogenic CNS indications through 2025.
−Removed: We are led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
−Removed: Our scientific founders, Dr.
−Removed: Stephen Squinto, Dr.
−Removed: James Wilson and Dr.
−Removed: Tadataka Yamada, are world leaders in research and development in the fields of rare disease and genetic medicine.
−Removed: Wilson’s and Dr.
−Removed: Yamada’s continuing relationship with our company and involvement in both academic research and clinical drug development allows us to gain early insight into emerging technologies that informs our business strategy.
−Removed: We have assembled a team whose members have extensive experience in successfully developing, manufacturing and commercializing rare disease and genetic medicine products at companies such as Allos Therapeutics, Biogen, GlaxoSmithKline, Janssen Pharmaceuticals, Lycera, Merck & Co., Momenta Pharmaceuticals, NPS Pharmaceuticals, Pharmasset, Ultragenyx Pharmaceutical and ViroPharma.
+Added: We believe our clinical product candidates have the potential to provide patients with significantly improved outcomes, given our chosen route of intra cisterna magna, or ICM, administration, the potential for enhanced benefits due to cross-correction of neighboring cells by secreted gene products, and our rigorous capsid and transgene selection process.
+Added: Our research collaboration with GTP provides us with access to one of the premier research institutions in the world for the discovery and preclinical development of genetic medicine product candidates and exclusive rights to product candidates for certain CNS disorders.
+Added: As part of this collaboration, we have exclusive rights to all
+Added: discovery work and IND-enabling research for product candidates in up to seventeen CNS indications that we select.
+Added: In addition to our three clinical product candidates, we have six ongoing research programs and eight remaining options available to us to license additional programs from GTP until May 2026.
+Added: We also have exploratory research programs with GTP in non-rare, non-monogenic, or large, CNS indications, initially focused on AD and TLE, which can be expanded to other large, CNS diseases upon mutual agreement with GTP.
+Added: Further, we have exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for our products developed with GTP, such as novel capsids, toxicity reduction technologies, delivery, and formulation.
+Added: We have global commercial rights to all of our current and future product candidates and believe that our approach to developing therapies for life-threatening diseases that are currently underserved presents an opportunity to efficiently advance our product candidates through clinical development, regulatory approval and ultimately to commercialization.
+Added: We are led by pioneers and experts with decades of collective experience in genetic medicines and rare disease drug development, manufacturing and commercialization.
+Added: Wilson, one of our scientific founders, is recognized as a world leader in research and development in the fields of genetic medicines and rare disease.
+Added: Wilson’s continuing relationship with our company and involvement in both academic research and clinical drug development allows us to gain early insight into emerging technologies that informs our business strategy.
+Added: We have assembled a team whose members have extensive experience in successfully developing, manufacturing and commercializing genetic medicine and rare disease products.
We have assembled a deep portfolio of genetic medicine product candidates for rare, monogenic CNS disorders characterized by high unmet medical needs.
−Removed: We intend to further expand our portfolio with genetic medicine product candidates for other rare, monogenic CNS disorders as well as other treatment approaches as technology advances in the field.
+Added: We intend to further expand our portfolio with genetic medicine product candidates for rare, monogenic and large CNS disorders, as well as other treatment approaches as technology advances in the field.
Our development programs consist of:
−Removed: 1 10 additional new pipeline license options
−Removed: 2 Program includes ongoing natural history study of infantile and juvenile GM1 gangliosidosis patients
PBGM01 for the treatment of GM1
2 unchanged sentences
β-gal is an enzyme that catalyzes the first step in the natural degradation of GM1 ganglioside.
−Removed: Reduced β-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressive neurodegeneration, with a life expectancy of two to four years.
+Added: Reduced β-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressive neurodegeneration, with a life expectancy of two to ten years.
Currently, there are no disease-modifying therapies approved for the treatment of GM1.
−Removed: Early onset infantile GM1 is characterized by onset in the first 6 months of life, while late onset infantile GM1 is characterized by onset between 6 and 24 months.
+Added: Early onset infantile GM1 is characterized by onset in
+Added: the first 6 months of life, while late onset infantile GM1 is characterized by onset between 6 and 24 months.
We believe PBGM01 could provide patients with significantly improved outcomes.
−Removed: In preclinical models, we have observed meaningful transduction of both the CNS and critical peripheral organs for GM1 patients using our ICM method of administration in combination with our next-generation AAVhu68 capsid, which involves an injection at the craniocervical junction.
−Removed: In December 2020, the U.S.
−Removed: Food and Drug Administration, or FDA, cleared our IND for PBGM01, which allows us to proceed with our clinical trial.
−Removed: We expect to initiate patient enrollment in our Imagine-1 Trial, an international multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1, in the first quarter of 2021.
−Removed: In December 2020, we received a CTA for our Imagine-1 Trial for PBGM01 from UK MHRA.
−Removed: In January 2021, we received a CTA for our Imagine-1 Trial for PCGM01 from Health Canada.
−Removed: We expect to report initial 30-day safety and biomarker data from the initial cohort mid-year 2021.
+Added: In preclinical studies we observed meaningful transgene expression in both the CNS and in peripheral organs affected in GM1.
+Added: We are conducting clinical trials using an ICM method of administration, which involves an injection at the craniocervical junction.
+Added: We have an active IND, or Investigational New Drug application, from the U.S.
+Added: Food and Drug Administration, or FDA, and approved clinical trial authorizations, or CTAs, in multiple countries for PBGM01, and we are actively proceeding with our Imagine-1 Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1.
+Added: In March 2021, we dosed the first patient in our Imagine-1 Trial.
+Added: In the fourth quarter of 2021, we reported initial safety and 30-day biomarker data from the initial cohort of two early onset GM1 patients treated with the low dose of PBGM01.
+Added: We also reported interim safety data for the initial cohort that showed PBGM01 was well tolerated with no series adverse events and no evidence of dorsal root ganglion toxicity.
+Added: In February 2022, we reported meaningful developmental improvement in assessments, utilizing the Bayley III and Vineland II scales, performed by trained healthcare providers and caregivers, respectively, for both patients in the initial cohort.
+Added: Additionally, in February 2022, we reported that we dosed our first patients in Cohort 2, for late onset infantile with high dose PBGM01, and Cohort 3, for early onset infantile GM1 with low dose PBGM01, with initial biomarker and safety data expected to be reported in the second half of 2022.
+Added: The FDA has granted Orphan Drug Designation, or ODD, Rare Pediatric Disease Designation, or RPDD, and Fast Track Designation, to PBGM01 for the treatment of GM1.
+Added: The European Commission has granted Orphan designation for PBGM01.
PBFT02 for the treatment of FTD-GRN
−Removed: We are currently developing PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN.
+Added: We are currently developing PBFT02, which utilizes an AAV1 capsid to deliver a functional copy of the granulin gene, or GRN, encoding for human progranulin, or PGRN, for the treatment of frontotemporal dementia caused by progranulin deficiency, or FTD-GRN.
FTD-GRN is an inheritable form of FTD in which patients have mutations in the GRN gene, causing a deficiency in PGRN.
−Removed: PGRN is a complex and highly conserved protein thought to have multiple roles in cell biology, development and inflammation.
−Removed: Emerging evidence suggests that PGRN’s pathogenic contribution to FTD and other neurodegenerative disorders relates to a critical role in lysosomal function.
+Added: PGRN is a complex and highly conserved protein thought to have multiple roles in cell homeostasis, neurodevelopment, and inflammation.
+Added: Emerging evidence suggests that PGRN deficiency in FTD and other neurodegenerative disorders may contribute to lysosomal dysfunction.
Currently, there are no disease-modifying therapies approved for the treatment of FTD-GRN.
−Removed: We believe PBFT02 may provide patients with significantly improved outcomes.
−Removed: In a non-human primate, or NHP, model, we observed superior transduction results of the CNS using our ICM method of administration and an AAV1 capsid compared to other AAV capsids.
−Removed: In January 2021, we received FDA clearance of our IND for PBFT02.
−Removed: We plan to submit CTAs to the United Kingdom, Italy, Brazil and Canada.
−Removed: We expect to initiate patient enrollment for a Phase 1/2 trial in the first half of 2021 and anticipate clinical data to be available in late 2021 or early 2022.
+Added: Based on findings in preclinical studies, we believe that PBFT02 may provide FTD-GRN patients with significantly improved outcomes.
+Added: We selected the AAV1 capsid and ICM administration for PBFT02 because this approach led to extensive and robust expression of human PGRN throughout the brain and spinal cord of NHPs, and due to the higher PGRN levels in CSF using AAV1 as compared with other serotypes tested.
+Added: ICM administration of AAV1 to NHPs resulted in CSF levels of human PGRN in excess of 50-fold higher than those in healthy human subjects’ CSF, and in excess of 5-fold higher than levels achieved in NHPs with AAVhu68 or AAV5.
+Added: We have an active IND from the FDA and approved CTAs in multiple countries for PBFT02, which allows us to proceed with our upliFT-D Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN.
+Added: We expect to dose the first patient in our initial cohort of our upliFT-D Trial in early 2022.
+Added: The FDA has granted ODD and Fast Track Designation to PBFT02 for the treatment of FTD-GRN and the European Commission granted Orphan designation for PBFT02.
PBKR03 for the treatment of Krabbe disease
We are currently developing PBKR03, which utilizes a proprietary, next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for Krabbe disease.
−Removed: Krabbe disease is an autosomal recessive lysosomal storage disease caused by mutations in the GALC gene, which provides instructions for making an enzyme called galactosylceramidase, which breaks down certain fats, including galactosylceramide and psychosine.
−Removed: This results in the accumulation of psychosine, resulting in widespread death of myelin-producing cells in the CNS and in the peripheral nervous system, or PNS.
+Added: Krabbe disease is an autosomal recessive lysosomal storage disease caused by mutations in the GALC gene, which provides instructions for making an enzyme called galactosylceramidase, which breaks down certain fats,
+Added: including galactosylceramide and psychosine.
+Added: This results in the accumulation of galactolipids such as psychosine, resulting in widespread death of myelin-producing cells in the CNS and in the peripheral nervous system, or PNS.
Without myelin, nerves in the brain and other parts of the body cannot transmit signals properly, leading to the signs and symptoms of Krabbe disease.
1 unchanged sentence
In preclinical models, we have observed meaningful transduction of both the CNS and other critical peripheral organs for Krabbe disease patients using our ICM method of administration in combination with our next-generation AAVhu68 capsid.
−Removed: In February 2021, we received clearance from the FDA on our IND for PBKR03.
−Removed: We plan to submit CTAs for PBKR03 in Canada, UK, Brazil, Netherlands, and Israel.
−Removed: We expect to initiate patient enrollment for a Phase 1/2 trial in the first half of 2021 and anticipate clinical data to be available in late 2021 or early 2022.
+Added: We have an active IND from the FDA and approved CTAs in multiple countries for PBKR03, which allows us to proceed with our GALax-C Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBKR03 in patients with a diagnosis of early infantile Krabbe disease.
+Added: We expect to dose the first patient in our initial cohort of our GALax-C Trial in early 2022.
+Added: The FDA has granted ODD, RPDD, and Fast Track Designation to PKBR03, and the European Commission granted Orphan designation for PBKR03.
Research Programs
−Removed: We also have four programs in the research stage under our license agreement with Penn:
−Removed: PBML04 for MLD, PBAL05 for ALS, PBCM06 for CMT2A and an undisclosed program to treat an adult CNS indication.
−Removed: PBML04 is targeting patients with MLD who have mutations in the ARSA gene, PBAL05 is targeting patients with ALS who have a gain-of-function mutation in the C9orf72 gene and PBCM06 is targeting patients with CMT2A who have a mutation in the MFN2 gene.
−Removed: Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for ten additional new indications in rare, monogenic CNS along with rights and licenses to new gene therapy technologies developed by Penn, such as novel capsids, toxicity reduction technologies and delivery and formulation.
−Removed: We are a genetic medicines company focused on developing transformative therapies for rare, monogenic CNS disorders with limited or no approved treatment options.
−Removed: Our vision is to finally fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with rare monogenic CNS diseases.
+Added: We have six programs in preclinical research stages under our license agreement with Penn:
+Added: PBML04 for MLD, PBAL05 for ALS, PBCM06 for CMT2A and unnamed programs for Canavan disease, Parkinson’s disease and Huntington’s disease.
+Added: PBML04 is in preclinical development for MLD, which is caused by mutations in the ARSA gene.
+Added: PBAL05 is targeting patients with ALS who have a gain-of-function mutation in the C9orf72 gene.
+Added: PBCM06 is in development for CMT2A, which is caused by a mutation in the MFN2 gene.
+Added: Our unnamed programs comprise of:
+Added: a program to treat patients with an inherited form of Parkinson’s disease with PRKN mutations;
+Added: a program for the treatment of Canavan’s disease, which is caused by mutations in the aspartyoacylase, or ASPA , gene;
+Added: and a program for the treatment of Huntington’s disease, a repeat expansion disorder.
+Added: Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for eight additional new indications in CNS diseases along with rights and licenses to new gene therapy technologies developed by Penn, such as novel capsids, toxicity reduction technologies and delivery and formulation.
+Added: We also have exploratory research programs with GTP for large indications, initially focused on AD and TLE, which can be expanded to other large CNS diseases upon mutual agreement with GTP.
+Added: We are a genetic medicines company focused on developing transformative therapies for CNS disorders with limited or no approved treatment options.
+Added: Our vision is to fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases.
To achieve our vision, we have assembled a world-class team whose members have decades of collective experience in genetic medicines and rare disease drug development and commercialization.
−Removed: We leverage this experience, along with the decades of experience of our scientific founders, Dr.
−Removed: Wilson and Dr.
−Removed: Yamada, as well as the transformative potential of genetic medicine technology to develop treatments that improve outcomes for patients with serious, life-threatening, rare diseases.
+Added: We leverage this experience, along with the decades of experience of Dr.
+Added: Wilson, as well as the transformative potential of genetic medicine technology to develop treatments that improve outcomes for patients with serious, life-threatening CNS diseases.
Patients are considered every step of the way, in every decision we make.
Key elements of our strategy include:
−Removed: • Focus on rare, underserved indications for which we can have a transformative impact on patients’ lives.
−Removed: We believe that genetic medicine has the potential to have a transformative impact on rare, monogenic CNS disorders, and on patients’ lives, by providing them with a treatment for life-threatening diseases with no approved disease-modifying treatments.
−Removed: • Rapidly advance our lead product candidates through clinical development through commercialization.
−Removed: We leverage our collaboration with GTP, as well as our internal capabilities, to select optimal product candidates for each indication based on extensive preclinical data, including animal data and disease-specific animal models and biomarkers, thus enhancing the probability of clinical success of our product candidates.
−Removed: Our goal is to select candidates that have the potential to address high unmet clinical needs and have transformative therapeutic effects for our patients.
+Added: • Focus on underserved indications for which we can have a transformative impact on patients’ lives.
+Added: We believe that genetic medicine has the potential to have a transformative impact on CNS disorders, and on patients’ lives, by providing them with a treatment for life-threatening diseases with limited or no approved disease-modifying treatments.
+Added: • Rapidly advance our clinical product candidates through clinical development and commercialization.
+Added: We leverage our collaboration with GTP, as well as our internal capabilities, to
+Added: select optimal product candidates for each indication based on extensive preclinical data, including animal data and disease-specific animal models and biomarkers, thus enhancing the probability of clinical success of our product candidates.
+Added: Our goal is to select candidates that have the potential to address high unmet clinical needs and have transformative therapeutic effects for patients.
If our clinical trials are successful, we plan to meet with regulatory authorities to discuss expedited regulatory approval strategies.
• Advance and expand our pipeline by identifying and developing additional product candidates into the clinic.
−Removed: We believe our differentiated drug development approach as well as our internal and partnered research capabilities may allow us to address a broad range of rare, monogenic CNS disorders, thus expanding our pipeline.
−Removed: Through our collaboration with GTP, we are continuing to develop additional genetic medicine product candidates targeting life-threatening, rare, CNS monogenic disorders.
−Removed: Beyond our three initial lead product candidates, we have four additional products advancing through the research stage.
−Removed: We also have the option to license ten additional rare, monogenic CNS indications from GTP through 2025.
+Added: We believe our differentiated drug development approach as well as our internal and partnered research capabilities may allow us to address a broad range of CNS disorders, thus expanding our pipeline.
+Added: Through our collaboration with GTP, we are continuing to develop additional genetic medicine product candidates targeting life-threatening CNS disorders.
+Added: Beyond our three clinical product candidates, we have six additional products advancing through the research stage.
+Added: We also have the option to license eight additional CNS indications from GTP until May 2026.
• Extend existing and establish new relationships with patients and patient advocacy groups.
2 unchanged sentences
These relationships deeply inform us as we develop and ultimately seek to commercialize our product candidates.
−Removed: Our relationship with Penn’s ODC, which is currently performing a natural history study for GM1 we are funding, represents an example of our strategy, and has been helping us to engage effectively with patients.
−Removed: We have also established a collaboration with Invitae to facilitate genetic
−Removed: testing and support early identification of GM1 through Invitae’s Detect Lysosomal Storage Disorders, as well as provide clinical trial information to physicians and patients.
+Added: Our relationship with Penn’s ODC, which is currently performing a natural history study for GM1 that we are funding, represents an example of our strategy, and has been helping us to engage effectively with patients.
+Added: We have a collaboration with Invitae to facilitate genetic testing and support early identification of GM1 and Krabbe disease through Invitae’s Detect Lysosomal Storage Disorders, as well as provide clinical trial information to physicians and patients, and have partnered with InformedDNA to offer free genetic counseling and testing for adults who have been diagnosed with FTD.
• Continue to develop proprietary manufacturing capabilities.
We believe the quality, reliability and scalability of our genetic medicine manufacturing techniques and know-how will be a critical advantage to our long-term success.
−Removed: We currently have access to a state-of-the-art purpose-fit manufacturing suite through Catalent Maryland (formerly Paragon Gene Therapy), a unit of Catalent Biologics, Inc., or Catalent.
−Removed: We expect this facility will be capable of producing supplies of our product candidates sufficient to conduct our clinical trials and potentially for initial commercial launch of our lead product candidates, if approved.
+Added: We currently have access to a state-of-the-art purpose-fit manufacturing suite through Catalent Maryland, a unit of Catalent Biologics, Inc., or Catalent.
+Added: We expect this facility will be capable of producing supplies of our product candidates sufficient to conduct our clinical trials and potentially for initial commercial launch of our clinical product candidates, if approved.
Catalent will also provide packaging, labeling and distribution services, including its FastChain® demand led supply offering, which we believe is well suited to studies of advanced therapy medicinal products.
−Removed: We expect to open our own laboratory in the second quarter of 2021, which will initially focus on state-of-the-art analytical capabilities, clinical assay development and validation, biomarker assay validation and clinical product testing to support both viral vector manufacturing and clinical development.
+Added: We have invested in our own laboratory, which is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development.
+Added: We also expect to open a pilot plant manufacturing suite to provide scale-up capabilities in support of our product pipeline and future development plans by the end of 2022.
We will continue to invest in developing our manufacturing capabilities and plan to establish our own manufacturing facility for long-term commercial supplies.
1 unchanged sentence
We will continue to foster our well-established relationship with Penn, and potentially enter into new collaborations to build our pipeline.
−Removed: We will look to nurture our genetic medicine technology capabilities by keeping abreast of advances in next-generation capsid development, promoter selection, transgene design, gene silencing and gene editing, which will help us to engineer optimal product profiles to address life-threating rare, monogenic CNS disorders characterized by high unmet medical needs.
+Added: We will look to nurture our genetic medicine technology capabilities by keeping abreast of advances in next-generation capsid development, promoter selection, transgene design, gene silencing and gene editing, which will help us to engineer optimal product profiles to address life-threating CNS disorders characterized by high unmet medical needs.
Genetic Medicine Background
3 unchanged sentences
Currently, there are estimated to be over 10,000 diseases caused by a genetic abnormality in a single gene.
−Removed: These are also known as monogenic diseases.
+Added: These are also known as monogenic
Based on research commissioned by us, we believe there are at least 790 rare monogenic CNS diseases, with few currently approved disease modifying treatments for any rare monogenic CNS diseases.
+Added: In addition, gene therapy can also be applied to correct biological pathways that are not necessarily inherited or associated with a defective gene.
+Added: This approach aims to reduce the expression of pathological proteins or increase the production of corrective biological targets.
+Added: This is the basis for the programs that target non-hereditary conditions such as sporadic AD and TLE.
The development of molecular therapeutics to modulate human gene expression and correct disease-causing genetic defects had its advent several decades ago, and with advances in science and a deeper understanding of human genetics it has expanded to include a broader range of genetic medicines with the potential to modulate gene expression through additional molecular mechanisms.
These transformative genetic medicines include gene therapy (delivery of an external gene to replace a defective gene), gene silencing (delivery of a DNA or ribonucleic acid, or RNA, based therapeutic that modulates the transcription or translation of an injurious gene product), gene editing (delivery of a DNA or RNA-based therapeutic that corrects the expression of targeted genes) and combinations of these therapeutic modalities.
−Removed: We believe that this expanded molecular biological tool box will provide new therapeutics with the potential to deliver highly potent and safe interventions across a diverse set of genetic diseases, offering several advantages, including:
+Added: We believe that this expanded molecular biological tool-box will provide new therapeutics with the potential to deliver highly potent and safe interventions across a diverse set of CNS diseases, offering several advantages, including:
• Potential to treat most diseases of genetic etiology.
5 unchanged sentences
Genetic medicines can be designed to mitigate challenges faced by other approaches in the development of therapeutics for the CNS.
−Removed: Rare, monogenic CNS disorders are among the most devastating in their impact on patients and their families.
+Added: CNS disorders are among the most devastating in their impact on patients and their families.
These disorders are generally life-threatening to patients.
−Removed: There is a significant need for genetic medicines that can target these genes because the brain is susceptible to mutations in single genes.
−Removed: Due to a historical preference in the drug industry to develop drugs for broader CNS indications, many of these rare CNS disorders currently have no approved therapies.
−Removed: We are focused on rare, monogenic CNS disorders because they offer a compelling opportunity for the effective application of genetic medicines.
−Removed: The field of genetic medicine is rapidly expanding and we believe we have developed a differentiated approach to developing treatments for rare, monogenic CNS disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success.
+Added: There is a significant need for genetic medicines that can target these disorders.
+Added: Our initial programs focus on rare, monogenic CNS disorders because they offer a compelling opportunity for the effective application of genetic medicines.
+Added: In the year ended December 31, 2021, we exercised options under the Penn Agreement to include Canavan disease and Huntington's disease to our portfolio, and also amended the Penn Agreement to broaden the scope under the Penn Agreement to include large CNS disorders, and entered into exploratory research programs to identify gene targets and develop therapeutic AAVs for large CNS disorders, initially TLE and AD.
+Added: The field of genetic medicine is rapidly expanding and we believe we have developed a differentiated approach to developing treatments for CNS disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success.
Our gene therapy product candidates use an AAV, a small, non-pathogenic virus that is genetically engineered to function as a delivery vehicle, or vector.
−Removed: The AAV is administered to a patient to introduce a healthy copy of a mutated gene to the cells in a process referred to as transduction.
+Added: In our current clinical programs, the AAV is administered to a patient to introduce a healthy copy of a mutated gene, or the transgene, to the cells in a process referred to as transduction.
+Added: Our current approaches use AAVs to deliver either a (i) replacement non-mutant transgene, or (ii) a combination of a microRNA, known as miRNA, and replacement of a non-mutant transgene.
The components of an AAV gene therapy vector include the therapeutic gene that makes up the DNA payload, or the transgene, the outer viral shell that encloses the DNA payload, or the capsid, and any promotors added to the vector to boost expression of the transgene.
The AAV is often described by the serotype, or strain, of the vector.
−Removed: The core tenets of our approach include a rigorous process for selecting product candidates, mitigation of early development risk through relationships with leading researchers and academic institutions, and mitigation of clinical development risk through deep relationships with patient advocacy groups, key opinion leaders and practitioners.
+Added: The core tenets of our approach include a rigorous process for selecting product candidates, mitigation
+Added: of early development risk through relationships with leading researchers and academic institutions, and mitigation of clinical development risk through deep relationships with patient advocacy groups, key opinion leaders and practitioners.
Together, these relationships allow us to directly benefit from decades of collective experience, the latest technologies and contemporary perspectives from patients and their experiences.
3 unchanged sentences
selection of the route of administration to maximize transgene biodistribution;
−Removed: selection of capsid, transgene and promoter to optimize efficiency of transduction and expression in the target tissue;
+Added: selection of capsid, transgene and promoter to optimize efficiency of transduction and expression;
leveraging biological mechanisms such as cross-correction to maximize availability of transgene product to target cells;
4 unchanged sentences
We will evaluate preclinical studies and other data to decide the preferred route of administration on a program-by-program basis.
−Removed: For our three lead product candidates, we believe that ICM delivery is the optimal route of administration as compared to other potential delivery mechanisms due to its diffuse delivery distribution, potential for improved biodistribution to the brain and spinal cord and transduction, and lower expected toxicity.
−Removed: Delivery through ICM can also reduce the potential impact of NAbs as compared with intravenous administration.
−Removed: We believe that by using ICM we can achieve comparable protein expression at lower dosages than would be required by other delivery routes.
+Added: For our three clinical product candidates, we believe that ICM administration is the optimal route of administration as compared to other potential delivery mechanisms due to its diffuse delivery distribution, potential for improved biodistribution to the brain and spinal cord and transduction, and lower expected toxicity.
+Added: Administration through ICM can also reduce the potential impact of NAbs as compared with intravenous administration.
+Added: We believe that by using ICM we can achieve comparable protein expression at lower dosages than would be required by other administration routes.
• Capsid, transgene and promoter selection:
3 unchanged sentences
• Cross-correction:
−Removed: Our three lead product candidates exploit the cross-correction mechanism by which secreted gene product from transduced cells is taken up by non-transduced neurons.
+Added: Our three clinical product candidates exploit the cross-correction mechanism by which secreted gene product from transduced cells is taken up by non-transduced neurons.
We believe this cross-correction mechanism can help overcome the limits of vector biodistribution and CNS transduction inefficiency that are characteristic of other genetic medicine approaches, and ultimately drive clinical benefit.
6 unchanged sentences
This collaboration provides us with access to differentiated discovery technology and expertise that informs the basis of our product candidate selection and subsequent development.
−Removed: Our strategic research collaboration with GTP provides us with access through 2025 to one of the premier gene therapy research institutes in the world for the discovery and preclinical development of gene therapy product candidates and exclusive rights to certain rare, monogenic CNS disorders, including next-generation AAV capsid technology and vector engineering, and state-of-the art preclinical animal studies, including NHP models.
−Removed: GTP currently employs approximately 300 staff with cutting edge expertise and capabilities in gene therapy research and preclinical development.
+Added: Our strategic research collaboration with GTP provides us with access until August 2026 to one of the premier gene therapy research institutes in the world for the discovery and preclinical development of gene therapy product candidates and exclusive rights to certain CNS disorders, including next-generation AAV capsid technology and vector engineering, and state-of-the art preclinical animal studies, including NHP models.
+Added: currently employs approximately 300 staff with cutting edge expertise and capabilities in gene therapy research and preclinical development.
Our collaboration with GTP allows us to choose programs that have been or will be validated through extensive testing in preclinical disease models, and once selected, to collaborate with GTP on further preclinical optimization of our product candidate, such as vector choice, transgene construct and route of administration.
We believe this collaboration improves our probability of technical and regulatory success in developing product candidates that provide transformative clinical benefits.
−Removed: Once we select a particular rare, monogenic CNS indication for further development, GTP, with our close involvement and oversight, embarks on a rational discovery and development program to design product candidates that may provide improved clinical benefit.
+Added: Once we select a particular CNS indication for further development, GTP, with our close involvement and oversight, embarks on a rational discovery and development program to design product candidates that may provide improved clinical benefit.
We usually evaluate transduction efficiency and biodistribution using multiple different capsids in NHPs to select the capsid best suited for the targeted indication.
1 unchanged sentence
We believe the translational preclinical characterization provided by GTP, including the use of NHP models for vector screening and toxicology, reduces the early-stage development risk of our product candidates.
−Removed: Pursuant to our discovery collaboration, GTP will also notify us of any new technologies it discovers, develops or engineers as part of its discovery program through 2025.
−Removed: We then have the option to acquire the right to use such new technologies for our product candidates for our selected indications.
Mitigation of Clinical Development Risk through Our Relationship with Penn’s ODC
8 unchanged sentences
The infantile form of the disease is characterized by onset in the first two years of life with symptoms including hypotonia (reduced muscle tone), progressive CNS dysfunction leading to deafness, blindness, enlarged liver and spleen, rigidity and progressive skeletal dysplasia that leads to restrictive lung disease and aspiration pneumonia.
−Removed: Early onset infantile GM1, also referred to as Type I, is characterized by onset in the first six months of life, while late onset infantile GM1, also referred to as Type IIa is characterized by onset between six and 24 months.
+Added: Early onset infantile GM1, or Type I, is characterized by onset in the first six months of life, while late onset infantile GM1, or Type IIa, is characterized by onset between six and 24 months.
The disease rapidly progresses, with a life expectancy of less than two years for early infantile GM1 and five to ten years for late infantile GM1.
−Removed: GM1 is caused by recessive mutations in the GLB1 gene, which encodes lysosomal acid beta-galactosidase, or β-gal, an enzyme that catalyzes the first step in the natural degradation of GM1 ganglioside.
+Added: GM1 is caused by recessive mutations in the GLB1 gene, which encodes lysosomal acid β-gal, an enzyme that catalyzes the first step in the natural degradation of GM1 ganglioside.
Reduced β-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressing neurodegeneration.
GM1 manifests as a continuum of clinical severity, ranging from infants with earlier onset and more severe and rapidly progressive disease to those with later juvenile or adult onset, slower progression and less severe manifestations.
−Removed: The global incidence of GM1 has been estimated to be 0.5 to 1 in 100,000 live births, with infantile GM1 representing approximately 62.5% of such cases.
+Added: The United States incidence of GM1 has been estimated to be approximately 1 in 100,000 live births, with infantile GM1 representing approximately 62.5% of such cases.
No states include GM1 in mandatory infant screening.
4 unchanged sentences
Program selection
−Removed: We chose GM1 as one of our lead clinical programs because it met our criteria for rare, monogenic CNS disorders in which we believe we can develop product candidates with a higher probability of technical and regulatory success and have a substantial impact on the lives of severely underserved patients.
−Removed: GM1 offers potential cross-correction, biomarker data and preclinical validation that are supportive of advancing GM1 into the clinic.
+Added: We chose GM1 as one of our initial lead programs because it met our criteria for rare, monogenic CNS disorders in which we believe we can develop product candidates with a higher probability of technical and regulatory success that will substantially impact on the lives of severely underserved patients.
+Added: Several key factors supported the decision to focus on GM1 for AAV gene therapy, as described below.
• Cross-correction :
−Removed: Following treatment with PBGM01, we expect newly synthesized β-gal to be secreted by transduced cells, which could provide a depot of secreted enzyme that could be taken up by other cells, resulting in the potential for cross-correction and broad CNS and peripheral organ enzyme replacement.
+Added: Following treatment with PBGM01, we expect that newly synthesized functional β-gal will be secreted by transduced cells and provide a source of secreted proteins that could be taken up by surrounding non-transduced and other wise enzyme-deficient cells.
+Added: This cellular cross-correction could therefore lead to enzyme replacement broad ly throughout the CNS and peripheral organ s .
• Biomarkers :
There are known biomarkers in GM1 that are measurable and available to assist in drug development.
−Removed: • Pharmacodynamic biomarkers.
+Added: o Pharmacodynamic biomarkers.
In our preclinical studies, biomarkers including β-gal activity and hexosaminidase, or HEX, activity showed treatment-related effects in PBGM01-treated GLB1 knockout mice.
−Removed: Cerebrospinal fluid, or CSF, collected at the time of necropsy showed β-gal activity exceeding that of disease-free heterozygous control mice.
−Removed: β-gal activity in the brains of PBGM01-treated GLB1 knockout mice was similar to normal control mice.
+Added: CSF collected at the time of necropsy showed β-gal activity exceeding that of disease-free heterozygous control mice.
+Added: β-gal activity in the brains of PBGM01-treated GLB1 knockout mice was similar to activity in normal control mice.
Peripheral organs, including the heart, lungs, liver and spleen, also exhibited elevated β-gal activity in PBGM01-treated mice.
−Removed: • Disease progression biomarkers.
−Removed: Recent MRI studies of infants with GM1 have shown longitudinal changes in infantile GM1 consistent with progressive brain atrophy and ventricular enlargement, suggesting that brain MRI would be a useful biomarker to detect and help verify treatment effects on disease pathophysiology.
+Added: o Disease progression biomarkers.
+Added: Recent MRI studies of infants with GM1 have shown longitudinal changes in MRI in infants with GM1 consistent with progressive brain atrophy and ventricular enlargement, suggesting that brain MRI would be a useful biomarker to detect and help verify treatment effects on disease pathophysiology.
• Preclinical validation:
−Removed: We used our GLB1 knockout mouse disease model showing both clinical and histological manifestations of GM1 in preclinical studies.
−Removed: In these studies, we observed a robust dose-related improvement in both neurological status, histologic lysosomal storage pathology and survival following treatment with PBGM01.
+Added: We used the GLB1 knockout mouse disease model showing clinical, biologic and histological manifestations of GM1 in preclinical studies.
+Added: In these studies, we observed a robust dose-related improvement in both neurological status, enzyme activity, histologic lysosomal storage pathology and survival following treatment with PBGM01.
Product Candidate Development Strategy
We have chosen the earliest and most severe form of GM1 for clinical development for several reasons.
−Removed: Within GM1, infantile GM1 represents the greatest medical need, as affected infants often do not survive two years, and thus are in immediate need of an effective therapy.
+Added: Within GM1, infantile GM1 represents the greatest medical need, as early onset GM1 infants often do not survive past two years, and thus are in immediate need of an effective therapy.
We expect treatment-related efficacy to be measurable sooner after treatment in this more rapidly progressing form of GM1.
−Removed: Children with onset forms of GM1 later than infantile are caused by less severe reductions of β-gal enzyme activity, generally demonstrate slower progression and more variable clinical courses, likely requiring larger and longer clinical trials and a broader control group.
+Added: Patients with onset forms of GM1 later than infantile, which we define as an onset later than 24 months, are caused by less severe reductions of β-gal enzyme activity, generally demonstrate slower progression and more variable clinical courses, likely requiring larger and longer clinical trials and a broader control group.
If our initial clinical trials in infantile GM1 are successful, we intend to explore expansion of the indication with trials in later onset forms of GM1.
Our Product Candidate
−Removed: We are developing PBGM01 to treat infantile GM1, with a single dose of PBGM01 by ICM injection.
+Added: We are developing PBGM01 to treat infantile GM1, with a single dose of PBGM01 by ICM administration.
PBGM01 utilizes a next-generation AAVhu68 viral vector to deliver modified DNA encoding the β-gal enzyme to a patient’s cells.
The goal of this vector and delivery approach is to increase levels of the β-gal enzyme in both the CNS and the peripheral tissues.
−Removed: We selected the AAVhu68 capsid and ICM route due to the superior transduction observed in cells of the CNS and peripheral organs, which are both affected in GM1 disease patients.
−Removed: Based on prior capsid comparison studies, we chose the AAVhu68 vector because it has the potential to provide corrective β-gal enzyme to both the CNS and peripheral tissues, which we believe gives us the potential to treat both the CNS pathologies and the peripheral manifestations observed in GM1 disease.
+Added: We selected the AAVhu68 capsid and ICM route of administration due to the superior transduction observed in cells of the CNS and peripheral organs, which are both affected in GM1 disease patients.
+Added: Based on prior capsid comparison studies, the AAVhu68 vector has the potential to provide corrective β-gal enzyme to both the CNS and peripheral tissues, which we believe gives us the potential to treat both the CNS pathologies and the peripheral manifestations observed in GM1 disease.
We believe gene replacement with PBGM01 and consequent wide brain distribution and uptake of the β-gal enzyme has the potential to greatly reduce the accumulation of GM1 gangliosides, reversing neuronal toxicity, thereby restoring developmental potential and improving the quality of life for treated patients.
−Removed: We will evaluate this clinically by assessing prevention of further developmental regression and restoration of developmental trajectories, as measured by developmental milestones using accepted clinical scales, observer reported outcomes and video recordings.
+Added: We will evaluate
+Added: this clinically by assessing the prevention of further developmental regression and restoration of developmental trajectories, as measured by developmental milestones using accepted clinical scales, observer-reported outcomes and video recordings.
Preclinical studies
−Removed: Proof of concept GLB1 Knockout Mouse Study
−Removed: Preclinical studies were conducted using a GLB1 knockout mouse model of GM1 (mice that carry homozygous mutations in the GLB1 gene, or GLB1—/—mice).
−Removed: The studies compared GLB1—/—mice treated with PBGM01, GLB1—/—mice treated with vehicle (phosphate-buffered saline, or PBS) and disease-free mice that are heterozygous GLB1 mutation carriers, or GLB1+/—mice, treated with vehicle.
−Removed: In this study, all mice were treated at one month of age and observed until four months of age, which is when GM1 mice typically develop marked gait abnormalities associated with brain GM1 ganglioside levels similar to those of infantile GM1 patients with advanced disease.
−Removed: All mice were treated with an intracerebroventricular, or ICV, injection of either PBGM01 (denoted in the following graphics as AAV) or vehicle.
−Removed: Ninety days after treatment, all animals were euthanized and tissues collected, referred to as necropsy, for histological and biochemical analysis.
−Removed: Serum β-gal activity was measured at various time points following treatment (days 0, 10, 28, 60 and 90).
−Removed: β-gal activity in the brain, CSF and peripheral organs were evaluated at the time of necropsy.
−Removed: The figure below shows that PBGM01-treated GLB1—/—mice had substantially higher serum β-gal activity following treatment than vehicle-treated GLB1—/—mice and similar β-gal activity to vehicle treated heterozygous control mice.
−Removed: Elevated serum β-gal activity as measured in nanomolar per milliliter per hour, or nmol/ml/h, was achieved shortly after treatment for all PBGM01-treated mice and persisted throughout the study for all but two PBGM01-treated mice, both of which exhibited antibodies against human β-gal.
−Removed: Serum β-gal activity
−Removed: The following figure shows β-gal activity in the brain as measured in nanomolar per milligram per hour, or nmol/mg/h, and CSF following necropsy.
−Removed: β-gal activity in the PBGM01-treated mice exceeded the vehicle-treated GLB1—/—mice in both the brain and the CSF.
−Removed: Treatment with PBGM01 increased β-gal activity in the brain and CSF in a knockout mouse model
−Removed: * p<0.05, **p<0.01, NS=not significant.
−Removed: Statistical significance is important and when used herein is denoted by p-values.
−Removed: The p-value is the probability that the reported result was achieved purely by chance (for example, a p-value < 0.001 means that there is a less than 0.1% chance that the observed change was purely due to chance).
−Removed: Generally, a p-value less than 0.05 is considered to be statistically significant.
−Removed: The following figure shows β-gal activity in the lungs, liver, heart and spleen following necropsy.
−Removed: In each organ, β-gal activity in the PBGM01-treated GLB1—/—mice exceeded activity levels in vehicle-treated GLB1—/—
−Removed: This data supports the potential of PBGM01 to provide corrective β-gal enzyme activity to peripheral organs and suggests that treatment with PBGM01 could address both the CNS and peripheral manifestations observed in GM1 patients.
−Removed: Treatment with PBGM01 Increased β-gal Activity in Peripheral Organs in A Knockout Mouse Model
−Removed: ** p<0.01, NS=not significant.
−Removed: We also assessed correction of brain abnormalities using biochemical and histological assays following necropsy.
−Removed: Lysosomal enzymes are frequently upregulated in lysosomal storage diseases, an observation that has been confirmed in GM1 patients.
−Removed: Therefore, we measured the activity of the lysosomal enzyme HEX in brain lysates.
−Removed: The figure below shows that the activity of HEX in PBGM01-treated GLB1—/—mice was normalized as compared to GLB1+/—control mice, while vehicle-treated GLB1—/—mice exhibited elevated total HEX activity.
−Removed: Treatment with PBGM01 normalized hexosaminidase activity in brain in a knockout mouse model
−Removed: ** p<0.01, NS=not significant.
−Removed: Histological analysis
−Removed: In addition to the knockout mouse model, we also performed a histological analysis comparing PBGM01-treated GLB1—/—mice to both vehicle-treated GLB1—/—mice and GLB1+/—control mice following necropsy.
−Removed: We evaluated lysosomal storage lesions by staining brain sections with filipin, a fluorescent molecule that binds GM1 ganglioside, as well as immunostaining for lysosomal-associated membrane protein 1.
−Removed: Filipin staining revealed marked GM1 ganglioside accumulation in neurons of the cortex, hippocampus and thalamus of the vehicle-treated GLB1—/—mice, which was normalized in the GLB1—/—mice treated with PBGM01.
−Removed: Immunohistochemistry demonstrated increased lysosomal membrane staining in the cortex and thalamus of vehicle-treated GLB1—/— mice, which was reduced in PBGM01-treated GLB1—/–mice similar to GLB1+/—control mice.
−Removed: Evaluation of Treatment-Effects on Neurological Function
−Removed: In order to evaluate neurological function in PBGM01-treated GLB1—/—mice, gait analysis was performed at four months of age (three months after PBGM01 or vehicle administration) over two consecutive days using the CatWalk XT gait analysis system, a commonly used assessment of motor performance in mice.
−Removed: Average walking speed and the length of the hind paw print were quantified for each animal across at least three assessments on the second day of testing.
−Removed: Slower speed and elongated paw prints are indicative of impaired motor performance.
−Removed: As shown in the figure below, walking speed and paw print length improved significantly in PBGM01-treated GLB1—/—mice compared to vehicle-treated GLB1—/—mice, and were similar to the GLB1+/—control mice.
−Removed: Treatment with PBGM01 Improved Gait Assessment in A Knockout Mouse Model
−Removed: *p<0.05, **p<0.01, NS=not significant.
−Removed: Dose Ranging Pharmacology Study
−Removed: A pharmacology study was conducted to evaluate the minimum effective dose, or MED, and β-gal expression levels in a GLB1 knockout mouse model of GM1 following ICV administration of PBGM01.
−Removed: In this study, GLB1—/— mice were ICV-administered with PBGM01 at four separate dose levels.
−Removed: Other GLB1—/—mice and heterozygous GLB1 mice were ICV-administered with vehicle.
−Removed: The mice were separated into two groups, with one group necropsied at day 150, or the Day 150 Group, and one group necropsied at day 300, or the Day 300 Group.
−Removed: There were twelve mice in each cohort in each group.
−Removed: In this study, ICV administration of PBGM01 resulted in stable, dose-dependent increases in transgene product expression in the brain and peripheral organs, resolution of brain lysosomal storage lesions, improvements in neurological phenotype and increased survival of GLB1—/—mice.
−Removed: The lowest dose evaluated is considered the MED based on statistically significant improvements in survival, neurological exam scores and brain storage lesions at that dose.
−Removed: Survival data
−Removed: The figure below shows survival data of each cohort in the Day 300 Group of the study.
−Removed: All 12 vehicle-treated GLB1—/—mice were euthanized according to the study defined euthanasia criteria prior to the scheduled study endpoint due to disease progression with neurological signs, characterized by ataxia, tremors and limb weakness.
−Removed: The median survival of this group was 268 days (185-283 days).
−Removed: In the lowest dose cohort, five of twelve mice were euthanized due to disease progression.
−Removed: In the second lowest dose cohort, one of twelve mice was euthanized due to disease progression.
−Removed: All mice in the two highest dose cohorts survived to the study endpoint.
−Removed: Survival Curves Following Administration of PBGM01 or vehicle
−Removed: Neurological examinations
−Removed: A standardized neurological examination was performed in a blinded fashion every 60 days through day 240, and an average total severity score was obtained.
−Removed: Data for the Day 150 Group and Day 300 Group were combined by treatment and genotype.
−Removed: The figure below shows average total severity score for each cohort as of each assessment period.
−Removed: The results of vehicle-treated GLB1—/—mice exhibited progressively higher total severity scores indicative of progressive neurological signs beginning at the day 120 assessment.
−Removed: At the lowest dose of PBGM01, a progressive increase in the total severity score was also observed at the day 120 assessment, although the total severity score was significantly lower than that of the vehicle-treated GLB1—/—mice at the same assessment point.
−Removed: At the second lowest PBGM01 dose, minimal abnormalities were detectable in seven of twelve mice at the day 240 assessment.
−Removed: At the two highest doses of PBGM01, neurological abnormalities were not apparent, and total severity scores for these groups were similar to those of the vehicle-treated GLB1+/—controls at each assessment point.
−Removed: Neurological Examinations Through Day 240
−Removed: Histological analysis
−Removed: A histological analysis was also performed comparing brain sections of PBGM01-treated GLB1—/—mice, vehicle treated GLB1—/—mice and vehicle treated GLB1+/—control mice at baseline, day 150 and day 300.
−Removed: Brain sections were stained for the lysosomal membrane protein LAMP1, and cortical cells positive for LAMP1
−Removed: (i.e., cells exhibiting lysosomal distention) were quantified in scanned sections using an automated program.
−Removed: For animals that did not survive to the scheduled day 300 necropsy due to disease progression (all animals survived to day 150), brains were collected at the time of euthanasia, and data are presented as part of the day 300 cohort.
−Removed: The results of this analysis are shown in the figure below.
−Removed: Untreated GLB1—/—baseline mice necropsied on day 1 exhibited a higher proportion of LAMP1-positive cells in the brain compared to that of untreated GLB1+/— baseline controls.
−Removed: At both day 150 and day 300, PBGM01-treated mice exhibited a dose-dependent reduction in the proportion of LAMP1-positive cells compared to vehicle-treated necropsied GLB1—/—controls.
−Removed: At the two highest doses of PBGM01, the proportion of LAMP1-positive cells were reduced to levels similar to those of vehicle-treated GLB1+/—controls at day 150 and day 300.
−Removed: β-gal activity
−Removed: β-gal activity was measured in serum on the day of dosing and every 60 days thereafter until day 240.
−Removed: At necropsy, β-gal activity was measured in the brain and peripheral organs (heart, liver, spleen, lung and kidney).
−Removed: As shown in the figure below, average β-gal activity in serum in GLB1—/—mice in the Day 300 Group administered the highest dose of PBGM01 was approximately 10-fold greater than that of vehicle-treated GLB1+/—controls.
−Removed: At the second highest dose of PBGM01, serum β-gal activity in GLB1—/—mice was similar to that of vehicle-treated GLB1+/—controls.
−Removed: Serum β-gal activity in GLB1—/—mice for all other PBGM01 doses was similar to that of vehicle-treated GLB1—/—controls.
−Removed: β-Galactosidase Activity in Serum of Glb1—/— Mice Treated with PBGM01 or vehicle (day 240)
−Removed: As shown in the figure below, β-gal activity was detectable in the CSF of all mice evaluated.
−Removed: GLB1—/—mice that were administered the two highest doses of PBGM01 displayed average CSF β-gal activity levels exceeding that of vehicle-treated GLB1+/—controls.
−Removed: CSF was not collected from vehicle-treated GLB1—/—mice because none survived to day 300.
−Removed: The shaded gray area in the figure below reflects the range of β-gal activity in CSF from GLB1—/—mice based on data from ten vehicle-treated animals from a prior study.
−Removed: β-gal activity in CSF was generally dose-dependent, although β-gal activity appeared to be similar in the two lowest dose groups.
−Removed: β-Galactosidase Activity in CSF of PBGM01-Treated GLB1—/—mice and Vehicle-Treated Controls (Day 300)
−Removed: The figures below show β-gal activity in the brain, heart and liver following necropsy.
−Removed: In the brain, β-gal activity increased in a dose-dependent manner in PBGM01-treated GLB1—/—mice.
−Removed: Average β-gal activity for all dose groups was higher than that of the vehicle-treated GLB1—/—controls.
−Removed: However, only the two highest dose groups exhibited higher average β-gal activity than that of the vehicle-treated GLB1+/—controls at both assessment points.
−Removed: Some peripheral organs also exhibited dose-dependent increases in β-gal activity after PBGM01 administration.
−Removed: The heart displayed dose-dependent increases in β-gal activity, resulting in average levels higher than that of vehicle-treated GLB1—/—mice at all doses.
−Removed: However, only the two highest doses restored β-gal activity to levels similar to or higher than that of vehicle-treated GLB1+/—controls at both assessment points.
−Removed: The liver displayed dose-dependent increases in β-gal activity after PBGM01 administration.
−Removed: At all doses except the lowest dose, average β-gal activity levels at both assessment points were higher than that of vehicle-treated GLB1—/—mice and similar to or higher than that of vehicle-treated GLB1+/—controls.
−Removed: β-Galactosidase Activity in Brain, Heart and Liver of PBGM01-treated GLB1—/—Mice and Vehicle-Treated Controls
+Added: The potential for efficacy of PBGM01 is supported by preclinical findings in GLB1 knockout ( GLB1-/-) mice.
+Added: This mouse line develops several characteristics that are reminiscent of the neurological presentation of GM1, including a rapid accumulation of GM1 ganglioside in the brain shortly after birth followed by progressive motor abnormalities and a shortened survival.
+Added: Intracerebroventricular, or ICV, injection of PBGM01 in GLB1-/- mice resulted in persistent dose-dependent elevations in β-gal activity in the brain, CSF, serum, and in peripheral organs.
+Added: Increased β-gal activity was associated with phenotypic and histopathological benefits in the GLB1-/- mice including the resolution of pre-existing brain lysosomal storage lesions as assessed by lysosomal associated membrane protein 1, or LAMP-1, immunohistochemistry, improved neurological phenotypes in assays of clinical deficits and animals’ gait, and increased survival.
+Added: Preclinical findings were published by GTP in 2020.
NHP Toxicology Study
−Removed: A 120-day good laboratory practice, or GLP, -compliant toxicology study was conducted in NHPs to assess the safety, tolerability and biodistribution and excretion (shedding) profile of PGM01 following ICM administration.
−Removed: Juvenile male and female rhesus macaques received a single ICM administration of vehicle or one of three dose levels of PGM01.
−Removed: Animals from each cohort were euthanized either 60 or 120 days following administration.
−Removed: In-life evaluations included clinical observations performed daily, multiple scheduled physical exams, standardized neurological monitoring, sensory nerve conduction studies, or NCS, body weights, clinical pathology of the blood and CSF, evaluation of serum-circulating NAbs and assessment of vector pharmacokinetics and vector excretion.
−Removed: Animals were necropsied, and tissues were harvested for a comprehensive histopathological examination, measurement of T-cell responses and biodistribution analysis.
−Removed: Key results from this study were:
−Removed: • ICM administration of PBGM01 was well-tolerated at all doses evaluated.
−Removed: PBGM01 produced no adverse effects on clinical and behavioral signs, body weight, or neurological and physical examinations.
−Removed: There were no abnormalities of blood and CSF clinical pathology related to PBGM01 administration except for a mild transient increase in CSF leukocytes in some animals.
−Removed: • I CM administration of PBGM01 resulted in vector distribution in the CSF and high levels of gene transfer to the brain, spinal cord and dorsal root ganglia, or DRG.
+Added: A 120-day good laboratory practice, or GLP, compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBGM01 following ICM administration of vehicle or one of three dose levels of PBGM01.
+Added: There were no blood or CSF abnormalities related to PBGM01 administration except for asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals.
+Added: PBGM01 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs.
+Added: Vector distributed to the CSF and high levels of gene transfer were detected in the brain, spinal cord and dorsal root ganglia, or DRG.
PBGM01 also reached high levels in peripheral blood and liver.
−Removed: • Evaluation of PBGM01 DNA excretion demonstrated detectable vector DNA in urine and feces five days after administration, which reached undetectable levels within 60 days.
−Removed: • T-cell responses to the vector capsid and/or human transgene product were detectable in the peripheral blood mononuclear cells and/or tissue lymphocytes (liver, spleen, bone marrow) in the majority of PBGM01-treated animals.
−Removed: T-cell responses were not generally associated with any abnormal clinical or histological findings.
−Removed: • Pre-existing NAbs to the vector capsid were detected in some animals and did not appear to influence gene transfer to the brain and spinal cord, although the presence of pre-existing NAbs correlated with reduced hepatic gene transfer.
−Removed: • Transgene expression and β-gal enzyme activity in CSF and serum of NHPs was limited by the nature of the assay, which could not distinguish human β-gal enzyme versus endogenous rhesus β-gal enzyme.
−Removed: The analysis was also complicated by the rapid loss of transgene product activity after Day 14, which was likely due to an antibody response to the human transgene product.
+Added: PBGM01vector DNA was detectable in urine and feces five days post-administration and was undetectable within 60 days.
+Added: Measurement of transgene expression by β-gal enzyme activity in CSF and serum of NHPs was limited by the nature of the assay, which could not distinguish human β-gal enzyme versus endogenous rhesus enzyme.
+Added: Rapid loss of transgene product activity after Day 14, which was likely due to an antibody response to the human transgene product, was an additional limitation.
Despite these caveats β-gal activity in the CSF and serum was detectable in animals from all dose groups 14 days after administration of PBGM01.
−Removed: • In the CSF, animals receiving the two higher doses displayed β-gal activity levels that were approximately two-fold and four-fold higher than the levels of vehicle-treated controls, respectively.
−Removed: Furthermore, expression in the CSF was not affected by the presence of pre-existing NAbs to the vector capsid, supporting the potential to achieve therapeutic activity in the CNS in infantile and late infantile patients with GM1 regardless of NAb status.
−Removed: • In serum, animals lacking pre-existing NAbs to the vector capsid trended towards higher β-gal enzyme activity compared to that of either the vehicle-treated controls or animals positive for pre-existing NAbs to the vector capsid.
−Removed: This result suggests the potential for therapeutic activity in peripheral organs for NAb-negative infantile and late infantile patients with GM1.
−Removed: • PBGM01 administration resulted in asymptomatic degeneration of the trigeminal ganglia, or TRG, and DRG sensory neurons and their associated central and peripheral axons.
+Added: In the CSF, animals receiving the two higher doses displayed β-gal activity levels that were approximately two- and four-times higher than vehicle-treated control levels.
+Added: Pre-existing NAbs to the vector capsid were detected in the serum of some animals and did not appear to influence gene transfer to the brain and spinal cord, or transgene product levels in the CSF.
+Added: This observation supports the potential to achieve therapeutic activity in the CNS in infantile and late infantile patients with GM1 regardless of NAb status.
+Added: Pre-existing NAbs to the vector capsid correlated with reduced gene transfer in the liver, however.
+Added: PBGM01 administration resulted in asymptomatic degeneration of the DRG and the trigeminal ganglia, or TRG, sensory neurons and their associated central and peripheral axons.
The severity of these lesions was typically minimal to mild.
These findings were not clearly dose-dependent, although there was a trend of more severe lesions in the mid-dose and high dose cohorts.
−Removed: Degeneration of sensory neuron cell bodies was less severe at day 120 than day 60, indicating that these lesions are not progressive, although the subsequent axon degeneration and fibrosis may continue to evolve over several months.
−Removed: Consistent with these findings, two animals that exhibited the most severe axon loss and fibrosis of median nerves upon necropsy at day 120 had exhibited a reduction in median nerve sensory action potential amplitudes by day 28 with no subsequent progression.
−Removed: Due to the presence of asymptomatic sensory neuron lesions in all dose groups, a no-observed adverse effect level was not defined.
−Removed: The figures below show the degeneration in the DRG, the spinal cord and median nerve axon and median nerve fibrosis as of day 120, as measured by histological analysis and scoring of severity of lesions from 0 (none) to 5 (severe).
−Removed: The two animals that exhibited the most severe axon loss and fibrosis with decreased sensory nerve action potential, or SNAP, are shown in red.
−Removed: Severity of DRG, Spinal Cord and Median Nerve Lesions at Day 120
−Removed: The figures below show the change in median sensory nerve conduction as of each measuring point in the study, as measured by median sensory action potential in microvolts.
−Removed: Median Sensory Nerve Conduction Studies
+Added: DRG and TRG lesions were less severe at Day 120 than Day 60, indicating they were not progressive.
+Added: Two animals that exhibited the most severe axon loss and fibrosis of median nerves at necropsy on day 120 also exhibited impairments in nerve conduction in terms of reduced sensory nerve action potential, or SNAP, amplitudes in the median nerve.
+Added: Reductions in SNAP amplitudes were evident by Day 28 with no subsequent progression.
+Added: This observation was consistent with the findings of a retrospective analysis of DRG pathology in NHPs after AAV administration conducted by GTP.
+Added: In an analysis of five preclinical studies, increased severity of axonopathy and fibrosis correlated with reduced SNAP amplitudes.
+Added: In keeping with the findings of the retrospective analysis, the PBGM01 -induced SNAP changes and sensory neuron degeneration were not associated with any clinical or neurological abnormalities in any animals up to 120 days post-dose .
+Added: In summary, based on our preclinical studies we believe that CSF delivery of PBGM01 has the potential to sufficiently increase b-gal levels in both the CNS and in peripheral tissues to overcome intracellular b-gal deficiency in GM1.
Clinical development
Our clinical development plan is to start with trials in infantile GM1, and if successful, explore expansion of the indication with trials in later onset forms of GM1.
−Removed: We expect to initiate patient enrollment of a multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1 beginning in the first quarter of 2021.
−Removed: Our initial cohort will be in patients with late infantile GM1, and we expect to report initial 30-day safety and biomarker data from this cohort mid-year 2021.
−Removed: We plan to specifically study early and late infantile patients in separate, smaller cohorts.
−Removed: We plan to enroll a total of four cohorts of two patients each, with separate dose-escalation cohorts for late onset infantile GM1 patients (with onset prior to 18 months in age) and early onset infantile GM1.
−Removed: This will test a low dose that exceeds the MED, as determined in our preclinical studies, and a 3-fold greater high dose.
−Removed: The first cohort will be in patients diagnosed with late infantile GM1 (greater than 12 months in age) with low dose treatment.
−Removed: There will be a 60-day interval between subjects dosed within a cohort to allow review of biomarker and safety data before dosing the next subject.
−Removed: Following the completion of this first cohort and review of safety outcomes, we will simultaneously commence recruitment for both the high dose late infantile GM1 and the low dose early infantile GM1 cohorts.
−Removed: Upon completion of the low dose early infantile cohort, a high dose cohort will be enrolled.
+Added: We initiated patient dosing in a multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1 in March 2021.
+Added: The study includes both early and late infantile patients in separate, smaller cohorts.
+Added: We plan to enroll a total of four cohorts of two patients each, with separate dose-escalation cohorts for late onset infantile GM1 patients , defined as onset prior to 24 months in age and after 6 months in age, and early onset infantile GM1 , defined as onset prior to 6 months of age .
+Added: The study is assessing an initial low dose (3.3x10˄10 genome copies/gm brain weight) that exceeds the minimum effective dose, or MED, as determined in our preclinical studies, and a 3-fold greater high dose (1.1x10˄11 genome copies/gm brain weight).
+Added: The first cohort includes patients diagnosed with late infantile GM1 .
+Added: There is a 60-day interval between all subjects dosed within a cohort to allow review of biomarker and safety data before dosing the next subject.
+Added: Clinical development results
+Added: We completed enrollment of the first cohort of two patients with late infantile GM1 receiving the initial low dose of PBGM01 in the second half of 2021 and reported interim safety and biomarker data in December 2021 .
+Added: The interim assessment included safety and biomarker results covering six months for patient 1 and 60 days for patient 2.
+Added: PBGM01 was well tolerated, with a positive safety profile, no serious adverse events, or SAEs, no complications related to ICM administration and no evidence of DRG toxicity.
+Added: β-gal activity in CSF and serum increased in both patients.
+Added: For patient 1, enzyme activity at 30 days was 1.5-fold over baseline and the increase was maintained at six months.
+Added: For patient 2, enzyme activity at 30 days was 4.8-fold over baseline.
+Added: In serum, enzyme activity for patient 1 was slightly above baseline at 30 days, 1.7-fold over baseline at three months, and maintained at six months.
+Added: Serum enzyme activity for patient 2 at 30 days was 1.2-fold over baseline.
+Added: CSF and serum β-gal activity for both patients rose above the enzyme concentrations documented in untreated infantile and juvenile GM1 participants in the ODC’s natural history study.
+Added: Large differences were observed in GM1 gangliosides in CSF at baseline, with patient 2, who was more severely affected, showing baseline values four times higher than patient 1.
+Added: In patient 1, CSF levels of GM1 ganglioside increased approximately 85 percent at 30 days and remained stable at that level at six months.
+Added: In patient 2, levels decreased approximately 46 percent at 30 days.
+Added: GM1 Cohort 1 interim data
+Added: Following the completion of this first cohort and review of safety outcomes, the Independent Data Monitoring Committee, or IDMC, recommended continuing the study with the recruitment for both the high dose late infantile GM1 and the initial dose early infantile GM1 cohorts.
+Added: The first patient in each of those two cohorts was dosed in early 2022 and we anticipate reporting initial data from these cohorts in the second half of 2022.
+Added: Upon completion of the initial low dose of the early infantile cohort, a high dose cohort is planned to be enrolled in that patient population.
Following these dose-escalation cohorts, each patient population will be enrolled into a confirmatory cohort.
1 unchanged sentence
We expect that pre-specified primary endpoints will include safety and efficacy.
−Removed: Efficacy will be evaluated by prevention of further developmental regression and by restoration of developmental trajectories, as measured by developmental milestones using accepted clinical scales, observer-reported outcomes and video recordings.
+Added: Efficacy will be evaluated by the assessment of developmental milestones using accepted clinical scales, observer-reported outcomes and video recordings.
Secondary outcomes will include serum and CSF β-gal enzyme activity and disease progression endpoints including evaluations using EEG and MRI.
−Removed: Our initial biomarker data will include blood and CSF β-gal enzyme activity.
−Removed: While blood β-gal activity is generally measurable due to the normal activity levels found in blood, it may be difficult to detect in the CSF due to lower normal activity levels in the CSF.
−Removed: We are working on improving our analytical capabilities to detect lower levels of B-gal activity.
−Removed: Due to our ICM delivery, we believe that if a treatment-related increase in blood B-gal activity is detected, this will suggest that there has also been a treatment-related increase in CSF β-gal enzyme activity.
+Added: In February 2022, we reported meaningful developmental improvement in assessments, utilizing the Vineland-II and Bayley-III scales, for both patients in the initial cohort, as outlined below.
+Added: These validated scales for assessing gross motor, fine motor, language and social development have been used previously in natural history studies.
+Added: The Vineland-II determines developmental milestones through structured interviews with caregivers, while the Bayley-III assesses developmental milestones through direct observation of skills by a trained healthcare professional.
+Added: Both assessments demonstrated progressive gains across all developmental areas which is not typical for children with GM1 late infantile.
+Added: Notably, patient 2, more severely affected at baseline than patient 1, was also documented to have regained previously lost motor and language developmental milestones.
+Added: Interim Clinical Results:
+Added: Vineland-II and Bayley-III:
+Added: Interim Clinical Results:
+Added: Vineland-II and Bayley-III:
Depending on the results from the dose escalation cohorts we plan to obtain input from regulatory agencies on the requirements to submit for regulatory approval for commercialization in the United States and internationally.
1 unchanged sentence
We are currently funding a GM1 natural history study being conducted by Penn’s ODC to collect prospective data on clinical disease progression in infantile and juvenile GM1.
−Removed: This data will be used to construct natural history patient profiles for use as matched case controls for comparison to the profiles of treated participants in our planned Phase 1/2 clinical trial.
−Removed: Regulatory Designations
−Removed: In April 2020, the FDA granted Orphan Drug Designation, or ODD, and in May 2020, the FDA granted Rare Pediatric Disease Designation, or RPDD, to PBGM01 for the treatment of GM1 gangliosidosis.
−Removed: We believe these designations represent an important recognition of the dire need for an effective treatment option for those suffering from GM1.
−Removed: The ODD grants us financial incentives to support clinical development and the potential for up to seven years of market exclusivity in the U.S.
−Removed: upon regulatory approval, while the under the RPDD program, a sponsor who receives approval for a drug or biologic for a “rare pediatric disease” may qualify for a priority review voucher that may be sold or transferred.
−Removed: In October 2020, the European Commission granted ODD to PBGM01.
−Removed: Clinical Trial Approvals
−Removed: In December 2020, the FDA notified us that our IND for PBGM01 was cleared, which allows us to proceed with our clinical trial.
−Removed: In December 2020 and January 2021, we also received approval of our CTA for our Imagine-1 Trial for PBGM01 from MHRA and Health Canada, respectively.
−Removed: We have manufactured the PBGM01 clinical supply and have established a clinical supply chain to support global clinical trial, including in the United States, the UK and Canada.
+Added: This data will be used to construct natural history patient profiles for comparison to the profiles of treated participants in our planned Phase 1/2 clinical trial.
+Added: Regulatory Designations and Clinical Trial Approvals
+Added: We have an active IND from the FDA and approved CTAs in multiple countries for PBGM01, and we are actively proceeding with our Imagine-1 Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1.
+Added: The FDA has granted Orphan Drug Designation, or ODD, Rare Pediatric Disease Designation, or RPDD, and Fast Track Designation, to PBGM01 for the treatment of GM1.
+Added: The European Commission has granted Orphan designation for PBGM01.
+Added: Through our manufacturing partners, we have manufactured the PBGM01 clinical supply and have established a clinical supply chain to support global clinical trials.
Overview of FTD-GRN
−Removed: FTD is one of the more common causes of early-onset (midlife) dementia, causing impairment in behavior, language and executive function, and occurs at similar frequency to Alzheimer disease in patients younger than 65 years.
−Removed: FTD presents as a rapidly progressive clinical syndrome.
−Removed: Changes in personal and social conduct occur in early stages of the disease, including loss of inhibition, apathy, social withdrawal, hyperorality (mouthing of objects) and ritualistic compulsive behaviors.
+Added: FTD is one of the more common causes of early-onset dementia, occurring with a median age of 55 years.
+Added: FTD presents as a rapidly progressive clinical syndrome and causes impairment in behavior, language and executive function.
+Added: Changes in personal and social conduct occur in early stages of the disease, including loss of inhibition, apathy, social withdrawal, hyperorality and ritualistic compulsive behaviors.
These symptoms are severely disabling and may lead to misdiagnosis as a psychological or emotionally based problem, or, in the elderly, be mistaken for withdrawal or eccentricity.
13 unchanged sentences
• Cross-correction:
−Removed: Following treatment with PBFT02, we believe overexpressing PGRN in a subset of cells in the CNS could provide a depot of secreted protein that could be taken up by surrounding cells, resulting in the potential for cross-correction and broad restoration of neuronal lysosomal function across the entire brain.
+Added: Following treatment with PBFT02, we believe overexpressing PGRN in a subset of cells in the CNS could provide a source of secreted protein that could be taken up by surrounding cells, resulting in the potential for cross-correction and broad restoration of neuronal lysosomal function across the entire brain.
• Biomarkers:
There are known biomarkers in FTD-GRN that are measurable and available to assist in drug development.
−Removed: • Pharmacodynamic biomarkers.
+Added: o Pharmacodynamic biomarkers.
PGRN is a secreted protein that can be measured in the CSF and plasma, and it has been shown to be reduced in the CSF of human GRN mutation carriers.
−Removed: • Disease progression biomarkers.
+Added: o Disease progression biomarkers.
We expect to be able to use recent progress in the identification of clinical disease progression biomarkers for FTD, including CSF, neuroimaging and retinal biomarkers, to facilitate clinical development by enabling early detection of treatment effects on disease pathophysiology.
• Preclinical Validation:
−Removed: In our preclinical studies in GRN—/—mice, ICV administration resulted in increased levels of PGRN in the CNS and CSF, with resolution of lysosomal storage lesions.
+Added: In our preclinical studies in GRN knockout mice, or GRN -/- mice, ICV administration of PBFT02 resulted in increased levels of PGRN in the CNS and CSF, with resolution of lysosomal storage lesions.
ICM administration in NHPs, which do not have the disease phenotype, resulted in robust increases in PGRN levels in CNS and CSF.
Our Product Candidate
−Removed: We are developing PBFT02 to treat FTD-GRN with a single dose of PBFT02 by ICM injection.
+Added: We are developing PBFT02 to treat patients affected with FTD-GRN with a single dose of PBFT02 by ICM administration.
PBFT02 is a gene therapy that utilizes an AAV1 viral vector to deliver a modified DNA encoding the GRN gene to a patient’s cells.
The goal of this vector and delivery approach is to provide higher than normal levels of PGRN to the CNS to overcome the progranulin deficiency in GRN mutation carriers, who have been observed to have reduced CSF PGRN levels ranging from 30% to 50% of the PGRN levels observed in normal, mutation non-carriers.
−Removed: We selected the AAV1 capsid and ICM delivery route due to the superior transduction of the transgene observed in NHP studies throughout the brain, including particularly high transduction of the ependymal cells that line the ventricles (CSF spaces) of the brain and secrete CSF, which circulates around the brain.
−Removed: Secretion of PGRN into the CSF by ependymal cells is expected to increase CSF levels of PGRN and the bioavailability of PGRN to other brain regions.
+Added: We selected the AAV1 capsid and ICM administration route due to the widespread and robust expression of the human PGRN transgene observed throughout the brain and spinal cord in NHP studies, and because levels of human PGRN in the CSF exceeded those measured in healthy human CSF (greater than 50 times), and those in NHPs that received AAV5 or AAVhu68 serotypes (greater than 5 times).
Preclinical studies
−Removed: Proof-of-Concept Pharmacology Mouse Model
−Removed: A pharmacology study was conducted in a mouse model using an AAVhu68 vector to assess whether delivery of the human GRN gene to the brain can elevate brain PGRN levels, eliminate existing lysosomal storage material and reduce the upregulated lysosomal enzyme HEX activity in GRN—/–mice (shown in the figures below as knockout, or KO, mice), which are present in the brain of GRN—/–mice as early as two months of age.
−Removed: Therefore, we treated GRN—/–mice at two to three months of age with an ICV injection of either an AAVhu68 vector expressing human GRN (shown in the figures below as AAV) or PBS vehicle, with ten mice in each group.
−Removed: In addition, a cohort of ten wild type, or WT, mice were injected with vehicle.
−Removed: Animals were euthanized 60 days after injection and necropsy was performed.
−Removed: Biomarker Evaluation
−Removed: The level of human PGRN protein in the brain and CSF (in nanograms per milliliter, or ng/mL) was measured using an enzyme-linked immunosorbent assay, or ELISA, to determine transduction levels.
−Removed: As shown in the figure below on the right, measurable levels of human PGRN were confirmed in the brain in the AAV-treated group, while in both the vehicle-treated and wild type groups, human PGRN was below detection levels.
−Removed: We further evaluated PGRN protein levels in the CSF, as shown in the figure below on the left.
−Removed: AAV-treated mice displayed a higher average CSF concentration of human PGRN than both the vehicle-treated and wild type groups.
−Removed: AAV Mediated Expression of Human PGRN (hPGRN) Protein in the CSF and Brain
−Removed: Histological analysis
−Removed: After confirming PGRN protein expression in the brain of GRN—/–mice, we assessed whether PGRN overexpression reduced the number of lipofuscin deposits in the hippocampus, thalamus and cortex.
−Removed: As shown in the figure below, AAV-treated GRN—/–mice exhibited fewer lipofuscin deposits (indicated by fluorescent spots) in all brain regions compared to those of vehicle-treated GRN—/–mice and comparable lipofuscin deposits to wild-type mice.
−Removed: Comparison of Lipofuscin Deposits in the Brain
−Removed: *p<0.05, ***p<0.001, ****p<0.0001
−Removed: Vector Comparison Study in Non-Human Primates
−Removed: PBFT02 utilizes an AAV1 vector to deliver to the brain a functional GRN gene encoding progranulin.
−Removed: The AAV1 vector was chosen over other potential vectors because it demonstrated a high tropism for the ependymal cells that line the brain ventricles in NHP studies.
−Removed: A study was conducted that was designed to evaluate the expression of human PGRN protein in the CSF of adult NHPs following ICM delivery of different AAV vectors.
−Removed: The primary goal of the study was to determine whether ICM AAV delivery could achieve CSF PGRN levels similar to those demonstrated to be pharmacologically active in the knockout mouse model, and to identify the vector capsid and transgene sequence that achieved the most robust expression.
−Removed: In the study, adult rhesus macaques received a single ICM injection of an AAV1, AAV5 or AAVhu68 vector expressing human GRN , with two NHPs per group.
−Removed: The AAVhu68 (v2) vector utilized a different GRN coding sequence and different promoter than what was used in the other vectors evaluated.
−Removed: Human PGRN protein was measured by enzyme-linked immunosorbent assay in the CSF and plasma.
−Removed: Increasing expression of PGRN outside of the CNS should not be required for the treatment of FTD-GRN, and the levels of PGRN protein in plasma was measured to ascertain if any of the vectors disproportionality increased PGRN outside of the CSF, which could cause potentially undesirable side effects.
−Removed: The figures below show that production of human PGRN protein in the CSF of all treated NHPs exceeded levels found in healthy normal human control samples.
−Removed: Production was highest in the CSF of NHPs treated with the AAV1 vector, resulting in concentrations more than 50-fold higher than normal human CSF PGRN concentrations.
−Removed: PGRN production in plasma was similar to normal human control levels for the AAVhu68 and AAV1 vectors.
−Removed: Plasma analysis was not performed on the AAVhu68 (v2) group.
−Removed: Production of Human PGRN Protein in CSF and Plasma of NHPs following ICM AAV Delivery
−Removed: In this NHP study, animals were necropsied 28 days after vector administration.
−Removed: Ependymal cell transduction was evaluated by immunohistochemistry in multiple regions of the brain of animals treated with AAVhu68 and animals treated with AAV1.
−Removed: As shown in the figure below, transduction of the ependymal cells (as shown by density of darkened ependymal cells) was substantially higher in the animals treated with AAV1 (48%) as compared to the animals treated with AAVhu68 (1-2%).
−Removed: Ependymal cell transduction following ICM delivery of AAV1 and AAVhu68 vectors expressing GFP in NHPs
−Removed: Based on the results from the NHP vector comparison study, we selected AAV1 as the capsid for our PBFT02 product candidate.
−Removed: In our NHP preclinical studies, the production of PGRN using a AAV1 capsid was 3 to 5 times greater than AAVhu68 and AAV5.
−Removed: Thus, we believe PBFT02 has the potential to provide a large CNS depot of progranulin that could be taken up by neurons broadly throughout the brain, restoring lysosomal function and neuronal survival, thereby slowing or stopping progression of the FTD.
−Removed: Further, AAV1 does not strongly transduce the liver and does not result in comparatively elevated levels of circulating PGRN.
−Removed: This may be an advantage by reducing the potential risk of unknown side effects of PGRN outside the CNS.
−Removed: GRN mutation carriers have been demonstrated to have reduced CSF progranulin levels ranging from 30% to 50% of the PGRN levels observed in normal, mutation non-carriers.
−Removed: Based on our preclinical studies, we believe that PBFT02 has the potential to sufficiently increase extracellular PGRN levels to overcome intracellular PGRN deficiency, without greatly increasing peripheral PGRN levels.
−Removed: Pharmacology Study in GRN —/— mice to determine the Minimally Effective Dose
−Removed: A pharmacology study was conducted to evaluate the MED in a GRN —/— mouse model following ICV administration of PBFT02.
−Removed: In this study, GRN— /— mice at 6.5 to 8.5 months old were administered PBFT02 at four separate dose levels and evaluated for 90 days.
−Removed: Other GRN— /—mice and wildtype mice were administered with vehicle.
−Removed: The initial age of administration was chosen because at this age, increased lipofuscin deposits and upregulated lysosomal HEX activity are observed in the brain of GRN—/— mice.
−Removed: This age also allowed evaluation of neuroinflammation, which develops later in disease progression, by 5 months of age.
−Removed: Thus, these mice mirror the developmental stage of the intended patient population (young/mature adult to middle-age adult) and allow evaluation of disease-relevant neuropathological features.
−Removed: As GRN —/— mice do not exhibit overt neurodegeneration or neurological symptoms, and they have a normal lifespan, the study duration was 90 days.
−Removed: The study duration was chosen to allow for evaluation following the expected onset, peak and plateau of transgene expression.
−Removed: Ninety days also allowed for detection of changes in the biochemical and neuropathological findings already present in the GRN—/— mice at the time of PBFT02 administration and was considered a sufficient duration for detecting post-treatment improvement in disease-relevant phenotypes.
−Removed: In this study, administration of PBFT02 to GRN —/— mice resulted in a dose-related correction of histopathology with the broadest treatment-related effects on lipofuscin, neuroinflammation and lysosomal enzyme activity observed at the highest dose.
−Removed: The lowest dose of PBFT02 was considered to be the minimally effective dose, as it significantly improved key neuropathological features found in patients with GRN -related neurodegeneration, including prevention of lipofuscin accumulation in the thalamus and a reduction in neuroinflammation defined by CD68 expression in the hippocampus.
−Removed: PGRN expression
−Removed: Human PGRN expression was measured in the CSF of necropsied mice 90 days after PBFT02 administration.
−Removed: As shown in the figure below, human PGRN expression in CSF increased at the two highest doses of PBFT02 compared to that of vehicle-treated GRN—/— controls.
−Removed: Human PGRN expression in GRN—/— mice administered the two lowest doses of PBFT02 appeared similar to that of the vehicle-treated GRN—/— mice and wild type controls.
−Removed: However, the limit of detection, or LOD, for the PGRN ELISA assay was 1.25 ng/mL, thus limiting the ability to detect changes in PGRN expression at the two lowest doses and in the vehicle-treated GRN—/— and wild type controls.
−Removed: PRGN Expression in CSF of GRN—/— Mice Administered PBFT02 or Vehicle
−Removed: Histological Analysis of Brain Abnormalities
−Removed: The thalamus, cortex and hippocampus were selected for quantification of lipofuscin deposits and CD68 expression because elevated lipofuscin accumulation and neuroinflammation/microgliosis are evident in these brain regions in GRN—/— mice.
−Removed: Furthermore, these brain regions exhibit extensive neuropathology in patients with GRN -related neurodegeneration.
−Removed: Lipofuscin deposits
−Removed: Lipofuscin deposits were quantified in three brain regions (thalamus, cortex and hippocampus) of mice necropsied at baseline and 90 days after PBFT02 administration, or Day 90.
−Removed: The figures below show that at both baseline and Day 90, lipofuscin deposits were more abundant in the thalamus compared to the cortex and hippocampus, suggesting that the thalamus might provide greater sensitivity for evaluating lipofuscin aggregates than the other brain regions.
−Removed: In the thalamus, a higher baseline lipofuscin count was observed in untreated GRN—/— mice than in untreated wild type controls.
−Removed: At Day 90, the average lipofuscin count in vehicle-treated GRN—/— mice was higher than that of the untreated GRN—/— baseline controls, indicating a progressive increase in lipofuscin deposits.
−Removed: In contrast, all PBFT02-treated groups displayed significantly lower lipofuscin counts than that of vehicle-treated GRN—/— mice.
−Removed: Because average lipofuscin counts in all PBFT02-treated groups were similar to that of the untreated GRN—/— baseline controls, PBFT02 administration at all dose levels appeared to prevent the progressive accumulation of lipofuscin during the 90-day study.
−Removed: In the cortex and hippocampus, higher average lipofuscin counts were also observed in vehicle-treated GRN—/— mice than in vehicle-treated wild type mice at Day 90.
−Removed: All PBFT02-treated dose groups displayed fewer average lipofuscin counts at Day 90 than vehicle-treated GRN—/— mice, although the reduction was only statistically significant in the cortex at the third highest dose.
−Removed: No dose-dependent response was observed, as lipofuscin counts were similar among all four PBFT02 dose groups.
−Removed: Quantification of Lipofuscin Deposits in the Brain of GRN—/– Mice Administered PBFT02 or Vehicle
−Removed: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
−Removed: Neuroinflammation
−Removed: The neuroinflammatory marker CD68 was quantified in three brain regions (thalamus, cortex and hippocampus) of necropsied mice at baseline and 90 days after PBFT02 administration.
−Removed: The figures below show that at baseline and on Day 90, higher average CD68 expression was observed in the thalamus, cortex and hippocampus of untreated GRN— /–mice when compared to that of untreated wild type controls.
−Removed: In the thalamus on Day 90, a generally dose-dependent response was observed with the three highest PBFT02 dose groups displaying significantly reduced CD68 expression compared to that of vehicle-treated GRN— /–mice.
−Removed: Of note, mice administered the highest dose of PBFT02 exhibited an approximately 4-fold reduction in CD68 expression compared to that of vehicle-treated GRN— /–mice.
−Removed: In the cortex on Day 90, average CD68 expression was reduced in all PBFT02-treated groups, although the reduction was not significantly different from CD68 expression in the vehicle-treated GRN— /–mice.
−Removed: No dose-dependent response was observed.
−Removed: In the hippocampus on Day 90, all PBFT02 dose groups displayed significantly lower CD68 expression compared to that of vehicle-treated GRN— /–mice.
−Removed: Moreover, CD68 expression was similar to that of vehicle-treated wild type controls for all doses of PBFT02.
−Removed: This response was not dose-dependent, as expression of CD68 was similar at all doses of PBFT02.
−Removed: Quantification of CD68 Expression in the Brain of GRN—/– Mice Administered PBFT02 or Vehicle
−Removed: *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001
−Removed: Lysosomal Enzyme Activity (Hexosaminidase Activity)
−Removed: A HEX activity assay was performed at baseline and 90 days after PBFT02 administration on lysates of the third frontal part of the brain, because lysosomal enzymes are frequently upregulated in lysosomal storage diseases, an observation that has been confirmed in GM1 patients.
−Removed: At baseline, brain HEX activity was higher in untreated GRN— /—mice than untreated wild type controls.
−Removed: At Day 90, GRN —/—mice administered the highest PBFT02 dose exhibited significantly reduced brain HEX activity compared to that of vehicle-treated GRN —/—mice.
−Removed: Moreover, HEX activity in the highest dose group was similar to that of vehicle-treated wild type controls, indicating normalization of brain HEX levels at this dose.
+Added: PBFT02 was selected as our development candidate based on initial proof-of-concept studies utilizing AAVhu68 and follow-up studies comparing multiple vector constructs for ability to elevate PGRN.
+Added: The initial proof-of-concept studies using an AAVhu68.hGRN construct in GRN knockout (GRN -/-) mice showed PGRN elevations and improved lysosomal function after vector doses that elevated CSF PGRN to approximately 10-fold over levels in healthy human controls and decreased deposits of lipofuscin, an electron dense marker of lysosomal dysfunction, broadly across the brain.
+Added: The AAV1 capsid was selected for PBFT02 following a study that evaluated the expression of human PGRN protein in the CSF of adult NHPs after ICM administration of four different vector constructs.
+Added: Proof of concept findings were published by GTP in 2020.
+Added: The comparison of AAVs in NHPs is shown in the figure below.
+Added: NHPs received a single ICM administration of commensurate doses of AAV1, AAV5, or AAVhu68 expressing the human GRN transgene with a CAG promoter (n=2/group).
+Added: A second tested AAVhu68 vector, or v2, utilized a different GRN coding sequence and a UBC promoter.
+Added: We found that the production of PGRN protein in the CSF rapidly exceeded levels found in healthy human control samples (“normal” line) in all AAV- treated NHPs .
+Added: AAV1 produced 50 times normal and greater than 5-10 times all other vectors tested.
+Added: Comparison of Vector Serotypes:
+Added: Production of Human PGRN-protein in CSF of NHPs following ICM-AAV administration.
+Added: Lower limit of quantitation, or LLOQ;
+Added: Healthy human control level, or Normal
+Added: We believe PBFT02 has the potential to provide supra-physiological levels of progranulin available to neurons broadly throughout the brain, restoring lysosomal function and thereby slowing or stopping the progression of FTD pathogenesis.
+Added: Further, ICM AAV1 did not strongly transduce the liver or significantly elevate levels of circulating PGRN, which may reduce the potential for unknown peripheral effects of PGRN.
+Added: The efficacy of the AAV1 vector was assayed in GRN -/- mice.
+Added: PBFT02 was administered via ICV delivery to adult mice at an age when lipofuscin deposition, lysosomal enzyme abnormalities, and neuroinflammation were present in brain regions involved in FTD-GRN pathophysiology including the frontal cortex, hippocampus, and thalamus.
+Added: This stage of disease progression was selected to be consistent with the developmental stage of the intended patient population of young to middle-aged adult.
+Added: Dose-dependent increases in human PGRN expression in the CSF following PBFT02 administration led to the correction of histopathologic and enzymatic changes in the mice.
+Added: Benefits included a reduction in the accumulation of lipofuscin, reduced neuroinflammation, and elevated lysosomal hexosaminidase activity in key brain regions.
NHP Toxicology Study
−Removed: A 90-day, GLP-compliant toxicology study was conducted in NHPs to assess the safety, tolerability and biodistribution and excretion (shedding) profile of PBFT02 following ICM administration.
−Removed: In this study, adult male and female rhesus macaques received a single ICM administration of vehicle or PBFT02 at one of three dose levels.
−Removed: Animals from each cohort were euthanized 90 days following administration.
−Removed: In-life evaluations included clinical observations performed daily, standardized neurological monitoring, sensory nerve conduction studies, or NCS, body weights, clinical pathology of the blood and CSF, evaluation of serum-circulating NAbs to the vector capsid, and assessment of vector pharmacokinetics and vector excretion.
−Removed: Animals were necropsied, and tissues were harvested for a comprehensive histopathological examination, measurement of T cell responses to the vector capsid and transgene product, biodistribution analysis, and evaluation of human PGRN expression and anti-human PGRN antibody responses.
−Removed: Key results from this study were:
−Removed: • ICM administration of PBFT02 was well-tolerated at all doses evaluated.
−Removed: All animals survived to the scheduled necropsy, and PBFT02 produced no adverse effects on clinical and behavioral signs, body weights, or neurologic examinations.
−Removed: There were no abnormalities of blood or CSF clinical pathology related to PBFT02 administration except for a mild transient increase in CSF leukocytes in some animals.
−Removed: • As shown in the figures below, PBFT02 administration resulted in asymptomatic degeneration of DRG and TRG sensory neurons (8 of 9 animals), along with their associated central and peripheral axons (9 of 9 animals).
−Removed: The severity of most of these lesions was minimal to mild.
−Removed: These findings showed a trend of more severe lesions in the mid-dose and high dose groups.
−Removed: Of the two animals that exhibited the most severe axon loss in the spinal cord and endoneurial fibrosis of peripheral nerves, one animal in the high dose group displayed a marked reduction in bilateral median nerve sensory action potential amplitudes on Day 90.
−Removed: • Pre-existing NAbs to the vector capsid were detectable in serum in 3 of 11 animals (27%) at baseline, and did not appear to influence gene transfer to the brain and spinal cord, although the presence of pre-existing NAbs correlated with markedly reduced hepatic gene transfer.
−Removed: T cell responses to the vector capsid or human transgene product were detectable in the majority of PBFT02-treated animals in
−Removed: peripheral blood mononuclear cells or tissue lymphocytes from the liver or spleen.
−Removed: T cell responses were not generally associated with abnormal clinical findings.
−Removed: • ICM administration of PBFT02 resulted in vector distribution in the CSF and high levels of gene transfer to the brain, spinal cord and DRG at Day 90.
−Removed: PBFT02 also reached significant concentrations in the peripheral blood, l l iver and spleen.
−Removed: Evaluation of PBFT02 vector DNA excretion demonstrated detectable vector DNA in urine and feces 5 days after administration, which reached undetectable levels within 60 days.
−Removed: • Human PGRN expression was detectable in CSF and serum in all animals by 7 to 14 days after PBFT02 administration.
−Removed: Human PGRN expression peaked between Days 14 to 28 in CSF and serum, and was generally dose-dependent.
−Removed: By Day 60, human PGRN expression in the CSF and serum declined from peak levels in all PBFT02-treated animals.
−Removed: This decline correlated with the appearance of antibodies against the transgene product (i.e., anti-human PGRN antibodies which are not expected to develop in haploinsufficient patients with FTD-GRN) in both CSF and serum of all PBFT02-treated animals.
−Removed: A comparison of the maximum expression of human PGRN in the CSF of NHPs to that of healthy human CSF showed that the mid and high doses of PBFT02 dose resulted in approximately 15-fold higher PGRN expression than that of healthy human CSF, while the lower dose of PBFT02 dose resulted in approximately 7-fold higher PGRN expression than that of healthy human CSF.
−Removed: We believe these pharmacology data support the possibility of achieving therapeutic PGRN expression levels and cross-correction in the CNS of FTD patients following ICM administration of PBFT02.
−Removed: Human PGRN protein
+Added: A 90-day GLP compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBFT02 following ICM administration at three dose levels.
+Added: There were no blood or CSF abnormalities related to PBFT02 administration except for asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals .
+Added: PBFT02 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs.
+Added: Vector distributed to the CSF and high levels of gene transfer were detected in the brain, spinal cord and DRG at Day 90.
+Added: PBFT02 also reached significant concentrations in the peripheral blood, liver and spleen.
+Added: PBFT02 vector DNA was detectable in urine and feces 5 days post-administration and was undetectable within 60 days.
+Added: Human PGRN was detectable in CSF and serum in all animals by 7 to 14 days after PBFT02 administration, peaking between Days 14 to 28, and was generally dose dependent.
+Added: Expression declined in all PBFT02-treated animals by Day 60, correlating with the appearance of antibodies against the human transgene product, which are
+Added: not expected to develop in haploinsufficient patients with FTD-GRN.
+Added: ICM PBFT02 administration to NHPs resulted in approximately 15-times higher PGRN levels in CSF than in CSF from healthy humans, while the low dose of PBFT02 resulted in approximately 7-times higher PGRN levels.
+Added: Pre-existing NAbs to the vector capsid were detected in the serum of 2 of 9 AAV-treated animals at baseline but did not appear to influence gene transfer to the brain and spinal cord, although their presence correlated with reduced hepatic gene transfer.
+Added: We believe that these data support the possibility of achieving supraphysiological PGRN levels in the CNS of FTD patients following ICM administration of PBFT02.
+Added: PBFT02 resulted in asymptomatic degeneration of DRG and TRG sensory neurons (8 of 9 AAV-treated animals), along with their associated central and peripheral axons (9 of 9 animals) at Day 90 post-administration.
+Added: The severity of these lesions was typically minimal to mild, with a trend to more severe lesions in the mid-dose and high-dose groups.
+Added: One PBFT02-treated animal exhibited a peripheral nerve conduction impairment in the median nerve, as detected by bilateral reductions in SNAP amplitudes on Day 28 and Day 90, that appeared to be treatment related as severe axon loss and endoneurial fibrosis were detected at necropsy.
+Added: PBFT02-induced SNAP changes and sensory neuron degeneration were not associated with any clinical or neurological abnormalities in animals up to 90 days post-dose.
+Added: In summary, based on our preclinical studies we believe that CSF delivery of PBFT02 has the potential to sufficiently increase extracellular PGRN levels in the CNS to overcome intracellular PGRN deficiency, without greatly increasing peripheral PGRN levels.
Clinical development
−Removed: Our clinical development plan is to treat FTD-GRN with a single dose of PBFT02 via ICM injection, with our initial clinical trial focused on early symptomatic FTD patients who have the GRN mutation.
−Removed: We have an active IND for PBFT02, and plan to initiate patient enrollment of a multi-center, open-label, single-arm Phase 1/2 dose escalation clinical trial of PBFT02 in patients with a diagnosis of FTD with a GRN mutation beginning in the United States in the first half of 2021.
−Removed: We expect to report initial 30-day safety and biomarker data from the first cohort in late 2021 or early 2022.
−Removed: This trial is expected to be a two-cohort dose-escalation trial, with three subjects per cohort and the potential for a third higher-dose cohort.
−Removed: The planned starting dose will exceed the MED in the GRN knockout mouse model, with planned escalation to a 3-fold higher dose.
+Added: Our clinical development plan is to treat FTD-GRN with a single dose of PBFT02 via ICM administration, with our initial clinical trial focused on early symptomatic FTD patients who have the GRN mutation.
+Added: We expect to dose the first patient in our initial cohort of our upliFT-D Trial in early 2022.
+Added: This trial is expected to be a two-cohort dose-escalation trial, with three subjects per cohort, and with a potential for a third higher-dose cohort, if considered necessary based on the results of the first two cohorts .
+Added: The planned starting dose (3.3x10˄10 genome copies/gm brain weight) will exceed the MED in the GRN knockout mouse model, with planned escalation to a higher dose (1.1x10˄10 genome copies/gm brain weight) .
The primary endpoint of the trial is to assess safety and tolerability over 60 months.
−Removed: Secondary endpoints are to assess change from baseline to 24 months on biomarkers, (including CSF and plasma progranulin levels, biomarkers of neurodegeneration and disease progression), and on clinical outcomes as measured by the Clinical Dementia Rating (CDR®) for improving evaluation of patients with frontotemporal lobar degeneration (FTLD), or CDR® plus NACC FTLD, and other neurocognitive assessments.
+Added: Secondary endpoints are to assess change from baseline to 24 months on biomarkers, including CSF and plasma progranulin levels, biomarkers of neurodegeneration and disease progression, and on clinical outcomes as measured by the Clinical Dementia Rating, or CDR®, for improving evaluation of patients with frontotemporal lobar degeneration, or FTLD, or CDR® plus NACC FTLD, and other neurocognitive assessments.
Interim analyses are planned for certain biomarkers starting at one month post dosing and for clinical outcomes beginning at one year post dosing.
−Removed: The independent data monitoring committee, or IDMC, will
−Removed: review 30-day biomarker data and safety data for each subject in a cohort.
+Added: The independent data monitoring committee, or IDMC, will review 30-day biomarker data and safety data for each subject in a cohort.
All subjects will be followed for a total of five years to monitor safety and selected biomarker and efficacy measures.
1 unchanged sentence
A scientific advice meeting with MHRA was held in November 2020, providing feedback on our proposed protocol.
−Removed: We also intend to seek feedback from other regulatory agencies outside the United States.
+Added: Feedback was also obtained from other regulatory agencies outside the United States.
Depending on the results from the initial cohorts, we plan to obtain input from regulatory agencies on the requirements to submit for regulatory approval for commercialization in the United States and internationally.
−Removed: Regulatory designations
−Removed: In January 2021, the FDA granted ODD to PBFT02 for the treatment of FTD-GRN.
−Removed: We believe this designation represents an important recognition of the dire need for an effective treatment option for those suffering from FTD-GRN.
−Removed: The ODD grants us financial incentives to support clinical development and the potential for up to seven years of market exclusivity in the United States upon regulatory approval.
−Removed: The FDA has recently granted Fast Track designation for PBFT02.
−Removed: Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat conditions and fill unmet medical need.
−Removed: Clinical Trial Approvals
−Removed: In January 2021, the FDA notified us that our IND for PBFT02 was cleared, which allows us to proceed with our clinical trial.
−Removed: We have manufactured the PBFT02 clinical supply to support clinical trial initiation in the United States.
+Added: Regulatory designations and Clinical Trial Approvals
+Added: We have an active IND from the FDA and approved CTAs in multiple countries for PBFT02, which allows us to proceed with our upliFT-D Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN.
+Added: The FDA has granted ODD and Fast Track Designation to PBFT02 for the treatment of FTD-GRN and the European Commission granted Orphan designation for PBFT02.
+Added: Through our manufacturing partners, we have manufactured the PBFT02 clinical supply to support clinical trial initiation.
Krabbe disease—PBKR03
Overview of Krabbe disease
−Removed: Krabbe disease is a rare and often life-threatening lysosomal storage disease that presents early the patient’s life, resulting in progressive damage to both the brain and PNS.
+Added: Krabbe disease is a rare and often life-threatening lysosomal storage disease that presents early in the patient’s life, resulting in progressive damage to both the brain and PNS.
Infants may present with extreme irritability and excessive crying, feeding difficulties, fisted hands, poor head control, stiffness and arching.
10 unchanged sentences
Most HSCT-treated children still have progressive gross motor delays ranging from mild spasticity to inability to walk independently, and limited use of their upper extremities.
−Removed: There is also a narrow window of treatment and, of course, a donor must be identified.
+Added: There is also a narrow window of treatment and a donor must be identified.
When performed after the onset of overt symptoms in these patients, HSCT provides only minimal neurologic improvement and does not substantially improve survival.
−Removed: Currently, nine states conduct mandatory screening for Krabbe disease and an additional four states passed legislation to include Krabbe disease in mandatory screening, but such screening has not yet been added.
−Removed: We engaged a third party data-analytics firm to conduct an analysis of screening data from the six states with screening history and based on this evaluation of screening data, we believe the incidence of Krabbe disease to be approximately 2.6 in 100,000 births.
+Added: Currently, ten states conduct mandatory screening for Krabbe disease and an additional four states passed legislation to include Krabbe disease in mandatory screening, but such screening has not yet been added.
+Added: We engaged a third-party data analytics firm to conduct an analysis of screening data from six states with screening history available to our third-party data analytics firm and based on this evaluation of screening data, we believe the incidence of Krabbe disease to be approximately 2.6 in 100,000 births.
Program Selection
−Removed: We chose infantile Krabbe disease as one of our first clinical programs because it met our criteria for rare, monogenic CNS disorders in which we believe we can develop product candidates with a higher probability of technical and regulatory success.
+Added: We chose infantile Krabbe disease as one of our initial lead programs because we believe we can develop product candidates with a higher probability of technical and regulatory success.
The indication presents cross-correction, biomarker data and preclinical validation that are supportive of advancing treatments for Krabbe disease into the clinic.
• Cross-Correction:
−Removed: Following treatment with PBKR03, newly synthesized galactosylceramidase is expected to be secreted by transduced cells, potentially providing a depot of secreted enzyme that could be taken up by other cells, resulting in the potential for cross-correction and broad CNS and PNS enzyme replacement.
+Added: Following treatment with PBKR03, newly synthesized galactosylceramidase is expected to be secreted by transduced cells and provide a source of secreted protein that could be taken up by surrounding cells, resulting in the potential for cross-correction and broad CNS and PNS enzyme replacement.
• Biomarkers:
There are known biomarkers in Krabbe disease that are measurable and available to assist in drug development.
−Removed: • Pharmacodynamic biomarkers.
+Added: o Pharmacodynamic biomarkers.
GALC activity has been shown to be reduced in patients with Krabbe disease and can be measured in CSF and plasma.
1 unchanged sentence
We will measure these biomarkers in CSF and plasma to assess the efficiency of transduction and restoration of GALC activity by PBKR03.
−Removed: • Disease progression biomarkers.
+Added: o Disease progression biomarkers.
We will leverage a number of neuroimaging, electrophysiological and fluid biomarkers to assess treatment effects on disease progression, including CNS myelination as measured by diffusion-tensor MRI, nerve conduction velocity, or NCV, to assess peripheral nerve myelin and conduction, and visual and brain stem-evoked potentials to assess CNS myelination and conduction.
5 unchanged sentences
PBKR03 utilizes a next-generation AAVhu68 capsid to deliver DNA encoding the GALC enzyme to a patient’s cells.
−Removed: PBKR03 will be administered as a single dose by ICM injection into the CSF.
−Removed: The AAVhu68 capsid and ICM route of administration were selected for the superior transduction observed in preclinical studies for cells of the CNS and PNS, which are both affected in Krabbe disease patients.
−Removed: This vector has the potential to provide corrective GALC enzyme to both the CNS and PNS, which we believe could treat both the CNS pathologies and the significant peripheral neuropathy observed in many Krabbe disease patients.
+Added: PBKR03 will be administered as a single dose by ICM administration into the CSF.
+Added: The AAVhu68 capsid and ICM route of administration were selected for PBKR03 due to observations in preclinical studies of robust transduction of targeted cells in the brain, and in DRG sensory neurons and spinal cord lower motor neurons.
+Added: Consequently, we believe that ICM PBKR03 has the potential to improve both the CNS pathologies and the significant peripheral neuropathies observed in many Krabbe disease patients.
Preclinical studies
−Removed: Vector Selection Study in Pre-Symptomatic Twitcher Mice
−Removed: A proof of concept study was conducted in pre-symptomatic twitcher mice to establish the route of administration, capsid and dose range best suited for treating infantile Krabbe disease.
−Removed: A twitcher mouse, denoted in the following figures as twi/twi, is a naturally-occurring mouse mutant caused by an abnormality in the gene coded for galactosylceramidase, and therefore is genetically equivalent to Krabbe disease.
−Removed: Four different AAV capsids encoding human GALC were tested:
−Removed: AAV3b, AAV5, AAV1 and AAVhu68.
−Removed: Each AAV vector was administered ICV.
−Removed: As a control, a group of pre-symptomatic twitcher mice were administered PBS vehicle only.
−Removed: As shown in the figure below, while all four capsids enhanced survival compared to the vehicle-treated control mice, the AAVhu68 capsid yielded superior survival over AAV3b, AAV5 and AAV1.
−Removed: Therefore, we selected the AAVhu68 capsid for subsequent studies.
−Removed: Survival Curves Following ICV Delivery of GALC to Presymptomatic Twitcher Mice Using Different AAV Capsids
−Removed: Pharmacodynamic Study in Twitcher Mice
−Removed: After selecting our AAVhu68 capsid for use, we then used the twitcher mouse model to examine treatment effects of PBKR03.
−Removed: In preclinical studies, PBKR03 was delivered into the CSF by ICV injection.
−Removed: As shown in the figures below, 28 days after ICV administration of PBKR03, GALC activity levels observed in the brain, liver and serum of PBKR03-treated twitcher mice were higher than the levels observed in the same tissues of vehicle-treated twitcher mice and healthy control mice (denoted by +/+ in the figure below).
−Removed: Pharmacology Study in Twitcher Mice
−Removed: A pharmacology study in early-symptomatic twitcher (twi/twi) mice was also conducted.
−Removed: Twitcher mice were ICV-administered PBKR03 on post-natal day, or PND, 12.
−Removed: Other age-matched early symptomatic twitcher mice, unaffected heterozygotes (twi /+ ) and wild-type (+/+) mice were ICV-administered PBS vehicle only on PND 12.
−Removed: PND 12 was selected as the day of dosing because it is shortly after the onset of PNS demyelination in an animal with brain maturation equivalent to a 2-month-old infant.
−Removed: Beginning ten days after administration, all mice were monitored daily for clinical signs.
−Removed: Clinical signs were scored using an assessment of clasping ability, gait, tremor, kyphosis, and fur quality.
−Removed: These measures effectively assess the clinical status of subject mice based upon the symptoms they typically present.
−Removed: Scores above 0 indicate clinical deterioration.
−Removed: Using this assessment, early-symptomatic twi/twi mice administered PBKR03 displayed clinical scores close to 0, which was comparable to the scores of unaffected twi /+ and +/+ mice, as shown in the figure below.
−Removed: In contrast, the age-matched vehicle-treated twi/twi mice displayed higher assessment scores over most of the time course, indicating clinical deterioration.
−Removed: Clinical Scoring
−Removed: As a complementary functional assay, the rotarod test, a commonly used test to evaluate motor coordination in mice, was performed on PND 35.
−Removed: As shown in the figure below, the early symptomatic PBKR03-treated twi/twi mice displayed fall latencies comparable to those of the unaffected twi /+ and +/+ mice, while the age matched vehicle-treated twi/twi mice displayed statistically significantly shorter fall latencies (p<0.05), indicating deterioration of neuromotor function.
−Removed: Complementary Functional Assay:
−Removed: Rotarod Day 35—Symptomatic Treatment
−Removed: To determine whether the observed benefits of PBKR03 administration on functional endpoints correlated with histologic improvements, all mice were necropsied 28 days following ICV administration, and the sciatic nerve of the hind limb was examined histologically.
−Removed: The sciatic nerve was selected for histology because peripheral nerves are more affected by demyelination in twi/twi mice compared to the CNS.
−Removed: As shown in the figures below, the sciatic nerve of vehicle-treated +/+ controls was enriched with myelin (dark blue staining) and generally devoid of globoid cell infiltrates (pink staining).
−Removed: However, in vehicle-treated symptomatic twi/twi mice, severe subtotal demyelination was observed in the sciatic nerve, accompanied by nerve thickening and the infiltration of globoid cells.
−Removed: In contrast, myelin was preserved in the sciatic nerve of symptomatic PBKR03-treated twi/twi mice, although not to the extent observed in age-matched +/+ mice.
−Removed: Fewer globoid cells were also observed in the nerve of PBKR03-treated twi/twi mice compared to vehicle treated twi/twi mice.
−Removed: Sciatic Nerve Histology Following ICV Administration of PBKR03 to Symptomatic Twitcher Mice:
−Removed: Pharmacology Study in Twitcher Mouse Model to determine the Minimally Effective Dose
−Removed: A pharmacology study was conducted to determine the MED and GALC expression levels in the twitcher mouse model of infantile Krabbe disease following ICV administration of PBKR03.
−Removed: In this study, juvenile twi/twi mice
−Removed: (postnatal day, or PND, 10 to 14) received a single administration of PBKR03 at one of four dose levels.
−Removed: Additional twi / twi mice and wild type mice were administered either vehicle or remained untreated as controls.
−Removed: The age of the animals was selected to model the disease stage of early-symptomatic infantile Krabbe disease patients.
−Removed: In this study, the MED was determined to be the third highest dose (out of four) because this dose led to significant improvements in survival, body wasting and failure to thrive (body weight loss), Krabbe disease-related clinical symptoms (clinical assessment scoring), and the prevention of phenotypic lymphopenia (suggestive of a reduction in autonomic neuronal degeneration) when compared to vehicle-treated controls.
−Removed: This dose increased myelination and reduced globoid cell infiltration and neuroinflammation in the brain, while also reducing globoid cell size in the brain and spinal cord compared to that seen in vehicle-treated controls.
−Removed: This dose was also the minimal dose leading to significantly increased GALC enzyme expression in the brain, which is a key target tissue.
−Removed: Naturally occurring Krabbe dog model
−Removed: The Krabbe dog is a naturally occurring autosomal recessive disease model derived from a spontaneous mutation in the GALC gene.
−Removed: The mutant GALC protein has residual enzymatic activity close to 0%, which is similar to GALC activity levels observed in patients with the infantile form of Krabbe disease.
−Removed: A preclinical study was conducted in the Krabbe dog model evaluating treatment with an AAVhu68 vector containing a codon-optimized canine GALC cDNA, which we refer to as AAV-treated dogs, or vehicle administered directly to the CSF using the ICM route of administration.
−Removed: In this study, four Krabbe dogs were treated with a single administration of PBKR03, two Krabbe dogs were treated with a sham and one wild type control dog was also treated with a sham.
−Removed: The two vehicle-treated Krabbe dogs reached the pre-defined humane endpoint, characterized by severe hind limb weakness and inability to stand and walk, on Day 35 or Day 66, which was consistent with the natural history of the disease.
−Removed: In contrast, all four PBKR03-treated dogs maintained normal motor function and did not reach the pre-defined humane endpoint associated with hind limb paralysis.
−Removed: One of the AAV-treated dogs was euthanized following a suspected seizure at 39 weeks.
−Removed: Prior to seizure, the animal exhibited normal phenotype.
−Removed: The pathology report revealed Krabbe-related lesions of demyelination and globoid cell infiltration that were less pronounced than vehicle-treated Krabbe dog controls, and similar to the two treated dogs from the 28 weeks scheduled necropsy timepoint.
−Removed: The spinal cord and peripheral nerve showed no demyelination, suggesting treatment effect was maintained and consistent with normal motor function of this animal prior to the seizure.
−Removed: Another of the AAV-treated dogs was euthanized at 19.5 months (82 weeks) of age due to body weight loss.
−Removed: The body weight loss was a result of recurrent vomiting and regurgitation.
−Removed: Following necropsy and histopathology of this dog, moderate demyelination and globoid cell infiltration of the vagus nerve, and moderate atrophy of the esophageal myenteric plexus was observed.
−Removed: Autonomic nerve (vagus nerve) dysfunction may be Krabbe disease-related and have contributed to weight loss in this dog.
−Removed: GALC expression
−Removed: As shown in the figure below, CSF GALC enzyme activity was detectable above baseline levels measured on Day 0 in all AAV-treated Krabbe dogs by 28 days post treatment.
−Removed: Levels were maintained at or above vehicle-treated wild type GALC activity levels for the duration of the study for each AAV-treated Krabbe dog, including up to 19.5 months post treatment.
−Removed: Expression levels in AAV-treated Krabbe dogs remained relatively stable for the duration of the study in most animals except Animal K933, which exhibited a notable peak in GALC enzyme activity on Day 28 followed by a decline to stable levels by Day 100 through 19.5 months post treatment.
−Removed: Finally, at Day 28 and Day 70, GALC enzyme activity levels in all AAV-treated Krabbe dogs exceeded that of the vehicle-treated controls prior to humane euthanasia.
−Removed: CSF GALC activity—AAV-treated
−Removed: Psychosine levels in CSF
−Removed: Psychosine was undetectable in the CSF of vehicle-treated wild type dogs from Day 0 through Day 180 post treatment.
−Removed: While psychosine was undetectable in the CSF of both vehicle-treated Krabbe dogs at baseline (Day 0), psychosine became elevated in both animals on Day 28, and levels increased further by the time of humane euthanasia.
+Added: Our Krabbe clinical program for PBKR03 is supported by robust pre-clinical proof of concept and pharmacology data in a naturally occurring GALC mutant mouse line, or Twitcher mice, in dogs with spontaneous GALC mutations, and in wildtype NHPs.
+Added: Preclinical data were presented by GTP in 2020 to the American Society of Gene & Cell Therapy’s, or ASGCT, 24th Annual Meeting and by us in 2021 at the 3rd Annual Gene Therapy for Neurological Disorders Congress.
+Added: To assess dose-dependent effects of PBKR03 in Twitcher mice, vector was administered via ICV delivery at the age of onset of peripheral demyelination.
+Added: PBKR03 dose-dependently improved histopathological, biochemical, and clinical disease signs.
+Added: The outcomes included increased GALC activity in the brain, serum, and in peripheral organs, which was associated with a significant reduction in histopathological markers of peripheral nerve damage including demyelination and globoid cell infiltration.
+Added: Related functional improvements included reductions in clinical symptoms as assessed by scores of neurological decline and improvements in motor balance, coordination, and activity.
+Added: PBKR03 administration to Twitcher mice also prevented the onset of lymphopenia, which often accompanies autonomic axon degeneration and significantly extended survival.
+Added: A preclinical study in Krabbe-affected dogs, or Krabbe dogs, evaluated treatment with an AAVhu68 vector containing a codon-optimized canine GALC cDNA, or vehicle, administered directly to the CSF using ICM administration.
+Added: Krabbe dogs express naturally occurring autosomal recessive mutations in the GALC gene that result in residual enzymatic activity close to 0%, which is similar to GALC activity levels observed in patients with the infantile form of Krabbe disease.
+Added: Four Krabbe dogs received a single ICM administration of PBKR03 at two to three weeks of age, while two age-matched Krabbe dogs and one wildtype dog received vehicle by the same route and served as controls.
+Added: AAV administration led to significant improvements in outcome measures in the Krabbe dogs.
+Added: The two vehicle-treated Krabbe dogs reached the study’s pre-defined humane endpoint of severe hind limb weakness and inability to stand and walk on Study Day 35 or Day 66, consistent with the rapidly progressing natural history of the disease.
+Added: In contrast, all of the four PBKR03-treated dogs maintained normal motor function for the duration of the study, and none reached the pre-defined humane endpoint associated with hindlimb weakness.
+Added: Two of the AAV-treated
+Added: dogs were euthanized at the scheduled necropsy timepoint of 28 weeks, and the remaining two were euthanized at 39 and 82 weeks of age, respectively.
+Added: One treated dog was euthanized following a suspected seizure at 39 weeks.
+Added: Prior to seizure, the animal exhibited normal phenotype including normal motor function.
+Added: Another of the AAV-treated dogs was euthanized at 82 weeks of age due to body weight loss following recurrent vomiting and regurgitation.
+Added: AAV-treatment elevated CSF GALC enzyme activity to above baseline levels by 28 days post-treatment in all dogs and maintained activity above that in vehicle-treated wildtype dog levels for the duration of the study, including up to 82 weeks in the longest-lived animal.
+Added: The pathological impact of GALC elevations was assessed by measuring the accumulation of the GALC substrate psychosine in CSF.
+Added: In the absence of GALC in Krabbe disease the cytotoxic substrate psychosine accumulates in the nervous system affecting oligodendrocytes and Schwann cells, leading to progressive demyelination.
+Added: Psychosine was undetectable in the CSF of vehicle-treated wildtype dogs from Day 0 through Day 180 post treatment.
+Added: In the vehicle-treated Krabbe dogs, while psychosine was undetectable in the CSF at baseline (Day 0), levels were elevated in both animals by Day 28 and increased further prior to their humane endpoints.
Elevations in psychosine correlated with the onset and progression of neurological symptoms in the vehicle-treated Krabbe dogs.
In contrast, psychosine was undetectable at most time points for all four AAV-treated Krabbe dogs.
−Removed: One animal exhibited undetectable levels of psychosine at all time points evaluated, while either mild or transient elevations were observed for the other animals.
−Removed: Nerve Conduction Studies
−Removed: As shown in the figures below, periodic NCV recordings demonstrated slowed or undetected signals in sham-treated Krabbe dogs, while all four AAV-treated Krabbe dogs had normalized velocities similar to the wild type control dog.
−Removed: Nerve Conduction Velocities in Motor and Sensory Nerves
−Removed: Brainstem auditory evoked response (BAER) pathway central conduction
−Removed: As hearing loss is common during Krabbe disease progression, hearing threshold under the Brainstem Auditory Evoked Response, or BAER, test was evaluated.
−Removed: Hearing threshold could not be determined (> 90 dB) in one vehicle-treated Krabbe dog but were similar to the vehicle-treated wild type dog in the other vehicle-treated Krabbe dog.
−Removed: All the treated Krabbe dogs had hearing thresholds similar to the vehicle-treated wild type dog for the entire duration of the study until euthanized at 19.5 months (82 weeks) of age.
−Removed: Histological Analysis
−Removed: A histological analysis evaluating myelination and neuroinflammation levels was also conducted.
−Removed: As shown in the figures below, all four AAV-treated Krabbe dogs exhibited increased myelination and reduced globoid cell infiltration in the brain, spinal cord and peripheral nerves by histology when compared to the vehicle-treated Krabbe dogs.
−Removed: Semi-Quantitative Scoring of Demyelination and Globoid Cell Infiltration in the Nervous System of Krabbe Dogs Following ICM Administration of AAV.
−Removed: As shown in the figure below, growth and body weight gain were normal in all treated dogs.
−Removed: One AAV-treated dog was euthanized due to weight body loss at 19.5 months of age (82 weeks).
−Removed: Age (weeks) Body Weight Curve
−Removed: Further, as shown in the figure below, after day 70, none of the dogs exhibited meaningful CSF pleocytosis, or increase in white cell count, with normal wild-type dog levels shown by the dotted line.
−Removed: There were no treatment-related histopathological lesions at 6 months in the AAV-treated Krabbe dogs.
−Removed: Clinical pathology (hematology and clinical chemistry)
−Removed: Three AAV-treated Krabbe dogs presented a mild and transient lymphocytosis 2 weeks post-injection.
−Removed: This finding is possibly treatment-related as it was not observed in the vehicle-treated Krabbe or wild type animals.
−Removed: It is not considered adverse due to low grade elevation and transient nature.
−Removed: There was no vector related modification of coagulation parameters nor serum clinical chemistry.
+Added: In the histological analysis, both vehicle-treated Krabbe dogs showed demyelination and globoid cell infiltration in the brain, spinal cord and peripheral nerves at post-mortem.
+Added: In contrast, all four AAV-treated Krabbe dogs showed no evidence of demyelination or globoid cell infiltration in the spinal cord, and reduced levels of each in the brain and in peripheral nerves.
+Added: AAV treatment also resulted in functional improvements in the Krabbe dogs.
+Added: In vehicle-treated Krabbe dogs, NCV in sensory and motor nerves was markedly impaired at the earliest assessment age of 6 weeks.
+Added: In contrast, in AAV-treated dogs, NCVs were similar to those in the wildtype control dog for the duration of the study, assessed up to 81 weeks of age in the longest-surviving dog.
+Added: Since hearing loss is common during Krabbe disease progression, animals’ hearing thresholds were evaluated by the Brainstem Auditory Evoked Response, or BAER, test.
+Added: One vehicle-treated Krabbe dog had a severe hearing impairment by 6 weeks of age with no determinable hearing threshold (> 90 dB), while the other vehicle-treated Krabbe dog was not hearing-impaired with a threshold similar to that in the wildtype dog.
+Added: All the treated Krabbe dogs had hearing thresholds similar to the vehicle-treated wildtype dog for the duration of the study, up to 81 weeks of age in the oldest dog.
+Added: In clinical pathology assessments, three AAV-treated Krabbe dogs presented with a mild and transient lymphocytosis two weeks post-injection.
+Added: This finding was considered possibly treatment-related as it was not observed in the vehicle-treated Krabbe or wildtype animals.
+Added: It was not considered adverse due to the low grade of elevation and its transient nature.
+Added: No vector-related modifications of coagulation parameters or serum clinical chemistry were detected.
Two AAV-treated Krabbe dogs presented transient mild CSF mononuclear pleocytosis 4 weeks post-injection.
−Removed: This finding is vector related and not considered adverse as it was self-limited and not accompanied by any neurological signs.
−Removed: GLP NHP Toxicology Study
−Removed: A 180-day GLP-compliant toxicology study was conducted in NHPs to assess the safety, tolerability and biodistribution and excretion (shedding) profile of PBKR03 following ICM administration.
−Removed: Juvenile male and female rhesus macaques received a single ICM administration of PBKR03 at one of 3 doses (low, med, high).
−Removed: Animals from each cohort were euthanized either 90 or 180 days following administration.
−Removed: In-life evaluations included clinical observations performed daily, physical exams, standardized neurological monitoring, sensory NCS, body weights, clinical pathology of the blood and CSF, evaluation of serum-circulating NAbs, assessment of vector pharmacokinetics and vector excretion, and evaluation of GALC enzyme expression and antibodies against anti-human GALC antibodies in CSF and serum.
−Removed: Key results from this study were:
−Removed: • ICM administration of PBKR03 was well-tolerated at all doses evaluated.
−Removed: PBKR03 produced no adverse effects on clinical and behavioral signs, body weights, or neurologic and physical examinations.
−Removed: There were no abnormalities of blood and CSF clinical pathology related to PBKR03 administration except for an asymptomatic mild transient increase in CSF leukocytes in some animals.
−Removed: • As shown in the figures below, PBKR03 administration resulted in minimal sporadic degeneration of primarily DRG sensory neurons, which led to a secondary degeneration of the associated central and peripheral axons (axonopathy).
−Removed: The DRG lesions were absent in some animals and minimal in severity when present.
−Removed: Secondary axonopathy associated with DRG lesions, while dose-dependent, was mostly minimal to mild.
−Removed: These findings were dose-dependent with a trend of more severe lesions in the mid-dose and high dose groups.
−Removed: The DRG findings and corresponding axonopathy were similar at Day 90 and Day 180, suggesting lack of progression.
−Removed: In the majority of the NHPs, findings were asymptomatic.
−Removed: A single animal in the high dose group exhibited a unilateral reduction in SNAP amplitudes in the left median nerve by Day 28 which correlated with endoneurial fibrosis in association with axonopathy in the left median nerve found at necropsy on Day 90 that correlated with a unilateral reduction in SNAP amplitudes in the left median nerve by Day 28.
−Removed: Due to the presence of asymptomatic sensory neuron lesions in all dose groups, the no-observed-adverse-effect level was not defined.
−Removed: Sensory Nerve Conduction Studies
−Removed: • Pre-existing NAbs to the vector capsid were detectable in serum in 11 of 18 PBKR03-treated animals at baseline, and NAb responses to the AAVhu68 capsid were subsequently observed in 18 of 18 PBKR03-treated animals by Day 28.
−Removed: Pre-existing NAbs to the vector capsid did not lead to abnormal clinical or histopathological findings.
−Removed: • T cell responses to the vector capsid or human transgene product were detectable in the majority of PBKR03-treated animals 15 of 18 in peripheral blood mononuclear cells or tissue lymphocytes.
−Removed: T cell responses to the human transgene product were more frequent and of higher magnitude than T cell responses to the vector capsid.
−Removed: T cell responses to the vector capsid were not affected by the presence of pre-existing NAbs to the vector capsid.
−Removed: T cell responses to the vector capsid or human transgene product were generally not associated with any abnormal clinical or histopathological findings.
−Removed: • GALC enzyme activity in CSF and serum was detectable in animals from all dose groups from the first time point evaluated.
−Removed: In CSF, animals receiving the two higher doses displayed GALC activity levels that were approximately two-fold and 1.75-fold higher than the levels of vehicle-treated animals, respectively.
−Removed: In serum, animals in all three dose groups exhibited GALC activity levels that were approximately 2-fold, 5.7-fold, and 6.6-fold higher than the levels of vehicle-treated animals, respectively.
−Removed: • Transgene product expression in CSF and serum was not affected by the presence of pre-existing NAbs to the vector capsid, which we believe supports the potential to achieve therapeutic activity in the target organ systems (CNS and PNS) in Krabbe disease patients regardless of NAb status.
−Removed: However, rapid loss of measurable transgene product activity was observed, which was attributable to an NHP antibody response to the foreign human transgene product in CSF and serum.
−Removed: This humoral response to the foreign human transgene product was not associated with abnormal clinical or histopathological findings.
+Added: This finding was vector-related and was not considered adverse as it resolved by 10 weeks post-injection and was not accompanied by any neurological signs.
+Added: NHP Toxicology Study
+Added: A 180-day GLP compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBKR03 following ICM administration at three dose levels.
+Added: There were no blood or CSF abnormalities related to PBKR03 administration except for asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals .
+Added: PBKR03 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs.
+Added: PBKR03 vector DNA was detectable in urine and feces 5 days post-administration, and was undetectable in urine within 60 days and in feces within 90 days in the majority of animals.
+Added: Human GALC expression, as measured by enzyme activity, was evaluated in CNS tissues and major organs of the AAV-treated NHPs, however detection was limited by the inability of the assay to distinguish between human and rhesus GALC activity and the high endogenous activity in NHPs.
+Added: Measurements were feasible in NHP CSF and serum, however, due to substantially lower endogenous GALC activities.
+Added: GALC activity was elevated in CSF and serum by 7 days after PBKR03 administration.
+Added: After the two higher doses, animals had CSF GALC activities
+Added: about 2-times higher than vehicle-treated animals.
+Added: In serum, GALC activity was increased approximately 2-times (low dose) to 6.6-times (high dose) over activity in vehicle-treated animals.
+Added: A rapid decline in serum GALC activity was observed after Day 14, which correlated with the onset of anti-human GALC antibody expression around Days 14 to 21.
+Added: The presence of pre-existing NAbs to the vector capsid in the serum of 11 of 18 AAV-treated animals did not appear to impact GALC activity in the serum or CSF, supporting the potential to achieve therapeutic transgene expression in Krabbe patients regardless of NAb status.
+Added: PBKR03 administration resulted in asymptomatic degeneration of primarily DRG sensory neurons along with their associated central and peripheral axons by Day 90 post-administration.
+Added: The severity of the lesions was typically minimal to mild, with a trend to more severe lesions in the mid-dose and high-dose groups.
+Added: DRG lesions did not progress between Day 90 and Day 180.
+Added: One animal in the high dose group exhibited a unilateral nerve conduction impairment in a median nerve, as detected by reduced SNAP amplitude on Day 28 and Day 90, that appeared to be treatment related as median nerve axonopathy and endoneurial fibrosis were detected at necropsy.
+Added: PBKR03-induced SNAP changes and sensory nerve degeneration were not associated with any clinical or neurological abnormalities in any animals up to 180 days post-dose.
+Added: In summary, based on our preclinical studies we believe that CSF delivery of PBKR03 has the potential to sufficiently increase GALC levels in both the CNS and in peripheral tissues to overcome intracellular GALC deficiency in Krabbe disease.
Clinical development
Our clinical development plan is to start with trials in early infantile Krabbe disease, and if successful, consider further exploration of expansion of the indication with trials in later onset forms of Krabbe disease.
−Removed: We believe gene replacement with PBKR03 could significantly reduce the accumulation of galactolipids such as galactocerebroside that often leads to demyleniation in both the CNS and PNS, or reduction in toxic glycosphingolipids of psychosine reversing neuronal toxicity, resulting in meaningful clinical benefit to patients.
−Removed: We will measure clinical benefit by prevention of further developmental regression and by restoration of developmental trajectories, as measured by developmental milestones using accepted clinical scales, observer-reported outcomes and video recordings.
−Removed: We have an active IND for PBKR03, and plan to initiate patient enrollment of a multi-center, open-label, single-arm Phase 1/2 dose-escalation clinical trial of PBKR03 in patients with a diagnosis of early infantile Krabbe disease GALC mutations and reduced enzyme activity beginning in the United States in the first half of 2021.
+Added: We expect to dose the first patient in our initial cohort of our GALax-C Trial in early 2022.
+Added: We believe that gene replacement with PBKR03 has the potential to have meaningful clinical benefit to Krabbe patients by significantly reducing neuronal demyelination and damage in both the CNS and PNS that results from the accumulation of galactolipids, such as galactocerebroside and psychosine.
+Added: We will measure clinical benefit by assessing developmental using accepted clinical scales, observer-reported outcomes and video recordings.
We intend this trial to have two independent dose escalation cohorts (three subjects per dose) based on age at enrolment:
dosing initially in subjects > 4 and < 9 months of age, with dose escalation and initiation of dosing in subjects > 1 and < 4 months of age gated by safety in cohort 1.
−Removed: Planned starting doses for each cohort will exceed the MED in the twitcher mouse model, with planned escalation to a 3-fold higher dose, followed by a third confirmatory cohort.
−Removed: We expect to report initial 30-day safety and biomarker data from the first cohort in late 2021 or early 2022.
+Added: Planned starting doses for each cohort will exceed the MED in the twitcher mouse model, starting with an initial low dose of 1.5 x 10˄11 GC/g estimated brain weight with planned escalation to a high dose of 5.0 x 10˄11 GC/g estimated brain weight , followed by a third confirmatory cohort using a dose selected on the basis of results from previous cohorts .
The primary endpoint of the trial is to assess safety and tolerability over 60 months.
2 unchanged sentences
All subjects will be evaluated over two years for safety and efficacy, followed by an additional 36 months of long-term follow up.
−Removed: We have also received feedback from the EMA regarding our preclinical studies and proposed clinical trial.
In collaboration with Penn’s ODC, we are also currently planning to develop comparator data sets for our Krabbe clinical trial.
1 unchanged sentence
Based on the results from this Phase 1/2 trial, we plan to obtain input from regulatory agencies on the requirements to submit for regulatory approval for commercialization in the United States and internationally.
−Removed: Regulatory Designations
−Removed: In October 2020, the FDA granted ODD and RPDD to PBKR03 for the treatment of Krabbe disease.
−Removed: We believe these designations represent an important recognition of the dire need for an effective treatment option for those suffering from Krabbe.
−Removed: The ODD grants us financial incentives to support clinical development and the potential for up to seven years of market exclusivity in the United States upon regulatory approval, while under the RPDD program, a sponsor who receives approval for a drug or biologic for a “rare pediatric disease” may qualify for a priority review voucher that may be sold or transferred.
−Removed: In February 2021, we received a positive opinion from the EMA for our orphan drug designation application for PBKR03 for the treatment of Krabbe disease.
−Removed: Clinical Trial Approvals
−Removed: In February 2021, the FDA notified us that our IND for PBKR03 was cleared, which allows us to proceed with our clinical trial.
−Removed: We have manufactured the PBKR03 clinical supply to support clinical trial initiation in the United States.
+Added: Regulatory Designations and Clinical Trial Approvals
+Added: We have an active IND from the FDA and approved CTAs in multiple countries for PBKR03, which allows us to proceed with our GALax-C Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBKR03 in patients with a diagnosis of early infantile Krabbe disease.
+Added: The FDA has granted ODD, RPDD, and Fast Track Designation to PKBR03, and the European Commission granted Orphan designation for PBKR03.
+Added: Through our manufacturing partners, we have manufactured PBKR03 clinical supply to support clinical trial initiation.
Trigeminal Ganglia and Dorsal Root Ganglia Toxicity
1 unchanged sentence
These findings have been previously reported as an AAV platform risk based on NHP studies in which minimal to mild DRG toxicity was observed within 14 to 30 days after dosing, without clinical manifestations.
−Removed: Chronic studies examining DRG toxicity have revealed no increase in severity and no clinical manifestations at four to six months or up to four years after
−Removed: administration.
+Added: Chronic studies examining DRG toxicity have revealed no increase in severity and no clinical manifestations at four to six months or up to four years after administration.
Similarly, no clinical manifestations were observed in any animals on detailed neurological examinations or daily observations in the PBGM01 and PBFT02 toxicology studies.
−Removed: We believe the asymptomatic sensory neuron findings observed in NHPs treated with AAV vectors via the ICM route likely represent a universal DRG pathology in NHPs administered AAV gene therapy.
+Added: We believe the asymptomatic sensory neuron findings observed in NHPs treated with AAV vectors via the ICM administration route likely represent a universal DRG pathology in NHPs administered AAV gene therapy.
Published data have shown that the administration of AAV vectors to NHPs via the blood or CSF can lead to damage of dorsal root ganglia and their associated axons.
5 unchanged sentences
Higher AAV doses correlated with increased severity.
−Removed: Younger NHPs (infants and juveniles) appeared to exhibit less severe pathology compared to adult NHPs.
+Added: Infant and juvenile NHPs appeared to exhibit less severe pathology compared to adult NHPs.
Animal sex and vector purification method had no impact.
3 unchanged sentences
To better understand the clinical significance of these findings, we plan to implement clinical monitoring in our GM1, FTD and Krabbe disease interventional trials, consisting of both nerve conduction studies and neurological exams focused on sensory and peripheral nerve function.
−Removed: The GTP has recently published data on certain technology regarding MicroRNA-mediated inhibition of transgene expression reduces DRG toxicity by AAV vectors.
−Removed: We plan to work with Penn to evaluate the appropriateness of incorporating this technology into our research programs, but do not expect to incorporate this early-stage technology into our current lead clinical programs for GM1, FTD or Krabbe.
+Added: GTP has recently published data on certain technology regarding microRNA-mediated inhibition of transgene expression reduces DRG toxicity by AAV vectors.
+Added: We plan to work with GTP to evaluate the appropriateness of incorporating this technology into our research programs, but do not expect to incorporate this early-stage technology into our current three clinical programs for GM1, FTD or Krabbe.
We have access to this technology as part of our collaboration with GTP, whereby we have access to novel capsids, toxicity reduction technologies and delivery and formulation improvements.
−Removed: Research Programs
−Removed: We also have four programs in the discovery, candidate selection or IND-enabling stage, PBML04 for MLD, PBAL05 for ALS, PBCM06 for CMT2A and an undisclosed program to treat an adult CNS indication.
−Removed: MLD is a monogenic autosomal recessive sphingolipid storage disease caused by mutations in the gene encoding the lysosomal enzyme ARSA.
−Removed: We have initiated IND-enabling studies for PBML04.
−Removed: Patients with MLD display progressive leukodystrophy (demyelination) in the CNS and PNS, neuronal cell death, and subsequent loss of all motor and cognitive function, resulting in premature death, especially in patients with early disease onset.
−Removed: PBAL05 is targeting ALS patients who have a gain-of-function mutation in the C9orf72 gene.
−Removed: ALS is a motor neuron disease characterized by rapid degeneration of upper and lower motor neurons, leading to progressive weakness and premature death.
−Removed: Most cases of ALS are sporadic with an unknown etiology, but there are also genetic forms of the disease inherited in an autosomal dominant fashion.
−Removed: Mutations in the C9orf72 gene are the most common genetic defects implicated in ALS, accounting for approximately 34% of familial ALS cases and approximately 5% of sporadic ALS cases.
−Removed: Mitofusin 2 , or MFN2, gene mutations are associated with CMT2A, which is a neurological disorder that presents complex phenotypes, including not only neuropathy-related features but also systemic impairment of the CNS.
−Removed: CMT2A is the most frequent axonal form of CMT, accounting for approximately 20% of the diagnosed cases.
+Added: Overview of MLD – PBML04
+Added: MLD is a monogenic autosomal recessive sphingolipid storage disease caused by mutations in the ARSA gene encoding the lysosomal enzyme arylsulfatase A, or ARSA.
+Added: Reduced ARSA activity leads to the progressive build-up of toxic sulfatides in neurons and glia in the central and peripheral nervous systems.
+Added: Neuronal cell death ensues with subsequent loss of motor and cognitive function, which is more severe and progresses faster in patients with early disease.
+Added: We are targeting infantile-onset MLD, which is characterized by progressive muscle weakness, rigidity and gait abnormalities, developmental delays, and is typically fatal by 5 years of age.
+Added: Estimations of worldwide prevalence of infantile-onset MLD vary within the range of 1 in 40,000 to 1 in 160,000 live births.
+Added: Our Product Candidate
+Added: We are developing PBML04, an AAVhu68 capsid expressing codon-optimized human ARSA , for ICM administration to increase the expression of ARSA in the CNS and periphery.
+Added: We expect to submit an IND application in mid-2022.
+Added: Preclinical Studies
+Added: PBML04 preclinical preliminary efficacy studies utilized a novel mouse strain developed using CRISPR/Cas9 gene deletion, by GTP in conjunction with Jackson Labs, which was presented at the 2021 ASGCT conference.
+Added: ARSA -/- mice develop a phenotype that recapitulates aspects of MLD from 9-10 months of age, including clinical deficits such as weight, balance, coordination, and gait deficiencies, sulfatide accumulation in central and peripheral neurons, lysosomal abnormalities, and increased neuro-inflammation.
+Added: In a preclinical study PBML04 treatment restored depleted ARSA activity in the brain and periphery.
+Added: In a 15 month-long study comparing three doses of PBML04 administered via ICV, functional improvements were shown in ARSA -/-, mice including significant improvements in an assessment of clinical motor performance and health, or the Neuroscore assay.
+Added: Further, while only 5 out of 10 of vehicle-treated ARSA -/- mice survived to the study endpoint 15 months post-treatment, all 30 PBML04-treated mice, which represents 10 per dose group, survived at the study end.
+Added: We are in the process of completing analysis on additional endpoints.
+Added: ARSA-/- Mouse Neuroscore
+Added: As shown in the figure below, four to five-month-old ARSA -/- mice or wildtype control mice were enrolled and scored on five parameters of clinical health and performance at baseline and at monthly intervals thereafter for 15 months.
+Added: The groups approximated to baseline age of five months for graphing.
+Added: The Neuroscore assay reflected the cumulative extent of impairment, generated by summing deficit scores of none to severe in five different parameters, including, posture, tremor, hind-limb clasping, gait and mobility, and grooming.
+Added: Maximum possible cumulative score was 17.
+Added: On Day 0 mice received PBML04 at one of three doses, which were low, medium, or high, or a vehicle control (n = 10 per group).
+Added: Data points show mean Neuroscores with standard error of the mean.
+Added: Wildtype mice showed little decline in Neuroscore assay up to 20 months of age, while vehicle-treated ARSA-/- mice showed a progressive decline over the 15-month study.
+Added: Onset and rate of decline in cumulative score was delayed and less severe in PBML04-treated ARSA-/- mice, and high dose-treated mice showed the least decline.
+Added: *** p < 0.001, statistically significant difference compared with vehicle-treated ARSA -/- mice (mixed effect model).
+Added: Abbreviations:
+Added: KO, ARSA -/- knockout mouse;
+Added: WT, wildtype mouse;
+Added: LD, low dose;
+Added: MD, mid dose;
+Added: HD, high dose.
+Added: Other Research Programs
+Added: We have five additional programs in candidate selection or discovery stages of preclinical research, in collaboration with GTP.
+Added: These include PBAL05 for ALS, PBCM06 for CMT2A, and our unnamed programs for Canavan disease, Parkinson’s disease and Huntington’s disease.
+Added: Overview of C9orf72 ALS - PBAL05
+Added: C9orf72-mediated Amyotrophic Lateral Sclerosis, or C9orf72 ALS, is an adult-onset, rapidly progressing neurodegenerative disease characterized by dysfunction and death of upper and lower motor neurons leading to progressive weakness, loss of motor function, and death typically within three to five years of disease onset.
+Added: Most cases of ALS are sporadic with an unknown etiology, but approximately 10% of patients have autosomal dominantly inherited forms.
+Added: We are focusing on C9orf72-mediated ALS, since mutations in the C9orf72 gene are the most common mutation found in ALS patients including both familial (approximately 40% of familial ALS cases) and sporadic ALS cases (approximately 8% of sporadic ALS patients carry C9orf72 mutations), accounting for approximately 11% of all ALS cases.
+Added: In 2020, prevalence of C9orf72 mutations were estimated to affect approximately 5,000 ALS patients worldwide.
+Added: In these cases, the disease is caused by a hexanucleotide repeat expansion in the first intron of C9orf72.
+Added: The pathogenic mechanism of C9orf72 mutations is not yet proven, but three potential mechanisms predominate, which are toxic gain of function arising from deposition of transcribed atypical dipepetide repeat proteins, and/or deposition of mutant ribonucleic acid, or RNA, and/or loss of function of endogenous proteins.
+Added: Our approach is to use a single AAV vector to deliver a miRNA and a codon-optimized miRNA-resistant C9orf72 transgene combination, to both deplete normal and mutant mRNA within cells with the miRNA and to replace with functional wildtype human transgene.
+Added: Preclinical pilot data showed that AAV-C9miRNA normalized elevated
+Added: toxic poly(GP) dipeptide repeat protein levels in mouse brains with a mutation in the C9-ALS gene.
+Added: This program is currently at the discovery stage.
+Added: Overview of CMT2A - PBCM06
+Added: CMT2A is a sensory and motor neuropathy caused by mutations in the gene encoding the mitochondrial protein mitofusin-2, or MFN2.
+Added: MFN2 is a GTPase that localizes to the outer mitochondrial membrane where it regulates mitochondrial fusion and mitochondrial binding to membranes of the endoplasmic reticulum.
+Added: CMT2A may present in childhood or adulthood, with progressive distal limb weakness, muscle atrophy, and loss of sensation.
Clinically, the classic form of CMT2A is characterized by physical weakness, foot deformities, difficulty in walking, and areflexia.
−Removed: We are coordinating with GTP in conducting discovery stage preclinical studies for these programs.
−Removed: Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for ten additional indications, along with rights and
−Removed: licenses to new gene therapy technologies developed by Penn, such as novel capsids, toxicity reduction technologies and delivery and formulation.
+Added: After early childhood onset, however, loss of ambulation by adulthood is common.
+Added: The worldwide prevalence is estimated to be approximately 1 in 100,000.
+Added: Our approach is to use a single AAV vector to deliver a miRNA and a codon-optimized miRNA-resistant MFN2 transgene combination, to both deplete normal and mutant mRNA within cells with the miRNA and to replace with a functional wildtype human transgene.
+Added: Preclinical pilot data identified lead construct that ameliorates distal limb weakness (grip strength) after ICV delivery in mice with a mutation in the MFN2 gene.
+Added: This program is currently at the discovery stage.
+Added: Unnamed Research Programs
+Added: With GTP we have three additional discovery stage preclinical programs, to develop genetic medicines for rare neurodegenerative disorders.
+Added: One, initiated in 2021, is a pediatric program to treat children with the inherited leukodystrophy Canavan's disease.
+Added: The other two programs address adult populations, one targeting a familial form of Parkinson's disease, and the other, which was also initiated in 2021, to treat Huntington's disease.
+Added: Programs are currently in discovery stages.
+Added: Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for eight additional indications.
+Added: Exploratory Research Programs
+Added: We also have an exploratory research program with GTP with the goal to develop genetic medicines for non-rare CNS disorders, initially focused on AD and treatment-resistant TLE, which can be expanded to other large CNS diseases upon mutual agreement with GTP.
Manufacturing
5 unchanged sentences
As part of our research collaboration with GTP, we have access to broad and deep early-stage process science capabilities and experience to enable technology transfer of scalable processes to our CDMO, and state-of-the art analytical capabilities for product quality testing and analytical characterization.
−Removed: GTP currently provides us with the preclinical and toxicology research-grade vector supplies, while Catalent provides us with the cGMP AAV clinical supplies for our clinical trials, following a technology transfer process from Penn to Catalent.
−Removed: The production process for all three of our lead candidates has been scaled up to GMP standards at Catalent’s facility and clinical materials for all three lead product candidates have been or are being manufactured.
−Removed: We have a collaboration agreement with Catalent, or the Catalent Collaboration Agreement.
−Removed: As part of the Catalent Collaboration Agreement, we paid Catalent an upfront fee for the commissioning, qualification, validation and equipping of a clean room suite.
−Removed: Subject to validation of the clean room suite, which was completed in the fourth quarter of 2020, we will pay an annual fee for five years for the use of the clean room suite.
−Removed: We initiated cGMP manufacturing in the dedicated suite, giving us the ability to meet production requirements for our current lead product candidates through clinical studies and early commercialization.
−Removed: We believe that our platform manufacturing approach along with the dedicated manufacturing capabilities and capacity provide a core strategic advantage and positions us to be a leading drug development company to address rare, monogenic CNS disorders.
−Removed: In April 2020, we entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for our gene therapy product candidates.
−Removed: The Manufacturing and Supply Agreement provides for a term of five years which period may be extended once, at our option, for an additional five year-period.
−Removed: In consideration for the use of the clean room suite, in addition to our annual fee, we have agreed to a minimum amount of purchase commitments for each year in the term, subject to adjustments for inflation.
−Removed: In December 2020, we entered into a lease to support chemistry, manufacturing and controls laboratory operations for our gene therapy programs.
−Removed: This new laboratory is slated to open in the second quarter of 2021 and will initially focus on state-of-the-art analytical capabilities, clinical assay development and validation, biomarker assay validation and clinical product testing to support both viral vector manufacturing and clinical development.
+Added: GTP currently provides us with the preclinical and toxicology research-grade vector supplies, while Catalent provides us with the cGMP AAV clinical supplies for our clinical trials.
+Added: The production process for GM1, Krabbe, FTD and MLD has been scaled up to GMP standards at Catalent’s facility and clinical materials for these candidates have been or are being manufactured.
+Added: We have a collaboration agreement with Catalent, or the Collaboration Agreement, that gives us access to a dedicated manufacturing suite .
+Added: We initiated cGMP manufacturing in the dedicated suite, giving us the ability to
+Added: meet production requirements for our current clinical product candidates through clinical studies and early commercialization.
+Added: We believe that our platform manufacturing approach along with the dedicated manufacturing capabilities and capacity provide a core strategic advantage and positions us to be a leading drug development company to address CNS disorders.
+Added: We also have a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for our gene therapy product candidates.
+Added: We entered into a lease to support chemistry, manufacturing and controls laboratory operations for our gene therapy programs, which commenced in March 2021 in Princeton West Innovation Campus.
+Added: In 2021, we completed our build out of this new laboratory that is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development.
We believe that our manufacturing capabilities provide us with the advantages of better control of drug development timelines, improved control of vector supply for a portfolio of clinical assets and improved control of product quality through the improvements of the manufacturing platform.
−Removed: We expect to establish our own manufacturing facility for long-term commercial market supply.
−Removed: As the research and development pipeline advances and grows, we intend to pursue internal manufacturing capacity build out as needed.
−Removed: We also anticipate that we will continue to make significant investments to further optimize our manufacturing capabilities to produce high-quality, cost-effective AAV vectors and we will continue to make investments in process and analytical sciences, internally or with third parties, to evaluate and develop manufacturing process improvements that may increase the productivity and efficiency of our manufacturing platform processes.
+Added: We also expect to open a pilot plant manufacturing suite at the Princeton West Innovation Campus to provide scale-up capabilities in support of our product pipeline and future development plans by the end of 2022.
+Added: We will continue to invest in developing our manufacturing capabilities and plan to establish our own manufacturing facility for long-term commercial supplies.
+Added: We also anticipate that we will continue to make significant investments to further optimize our manufacturing capabilities and platforms to produce high-quality, cost-effective AAV vectors and we will continue to make investments in process and analytical sciences, internally or with third parties, to evaluate and develop manufacturing process improvements that may increase the productivity and efficiency of our manufacturing platform processes.
The biotechnology and pharmaceutical industries, including the genetic medicines field, are characterized by rapidly changing technologies, competition and a strong emphasis on intellectual property.
1 unchanged sentence
We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions with genetic medicine and other therapeutic approaches.
−Removed: We consider our most direct competitors with respect to PBGM01 for the treatment of GM1 to be Sio Gene Therapies, Inc., which began its clinical trial for a gene therapy treatment for early and late infantile and juvenile GM1 in August 2019, and Lysogene, S.A., has received MHRA and Research Ethics Committee approvals in the United Kingdom in January 2021 and received IND clearance from FDA in February 2021 to start a Phase 1 clinical trial for a gene therapy treatment for GM1.
−Removed: We consider our most direct competitors with respect to PBFT02 for the treatment of FTD-GRN to be Alector, Inc., which is conducting a Phase 2 clinical trial for immune-neurology treatment for FTD-GRN, and Prevail Therapeutics Inc., which was acquired by Eli Lilly and Company in January 2021, has initiated a Phase 1/2 clinical trial for a gene therapy treatment for FTD-GRN.
−Removed: Alkermes plc and Arkuda Therapeutics, Inc.
−Removed: are conducting preclinical research using small molecule approaches to treat FTD-GRN patients.
−Removed: Denali Therapeutics has a preclinical recombinant progranulin protein under evaluation in addition to their oral EIF2a modulator in a Phase 1 clinical trial.
+Added: We consider our most direct competitors with respect to PBGM01 for the treatment of GM1 to be Sio Gene Therapies, Inc., or Sio, and Lysogene, S.A, or Lysogene.
+Added: Sio is conducting its clinical trial for an IV gene therapy treatment for early and late infantile/juvenile GM1 and reported data from ten patients in October 2021.
+Added: Lysogene, as of February 2022, reported having dosed three patients and enrolled a fourth patient in the safety cohort, after which Lysosgene will initiate treatment of twelve patients in the efficacy confirmatory cohort of its Phase 1/2 clinical trial for a gene therapy treatment administered via intracisternal magna for early and late infantile GM1.
+Added: We consider our most direct competitors with respect to PBFT02 for the treatment of FTD-GRN to be Alector, Inc.
+Added: (partnered with GlaxoSmithKline), which is enrolling a Phase 3 clinical trial with a humanized anti-human sortilin monoclonal antibody for FTD-GRN, and Prevail Therapeutics Inc.
+Added: (now part of Eli Lilly & Co), which has initiated a Phase 1/2 clinical trial for a gene therapy treatment for FTD-GRN, and is expected to continue enrolling through 2023.
+Added: Several other companies, including Applied Genetic Technologies Corporation, Orchard Therapeutics plc, AcuraStem Inc.
+Added: and Shape Therapeutics Inc., are conducting preclinical research using gene therapy approaches to treat FTD-GRN patients.
+Added: Denali Therapeutics Inc.
+Added: in partnership with Takeda Pharmaceutical Company Limited has a preclinical recombinant progranulin protein under evaluation in addition to their oral EIF2a modulator in a Phase 1 clinical trial.
We are also aware of other therapeutic approaches in preclinical development that may target FTD-GRN patients.
−Removed: Recently Forge Biologics announced that FDA granted IND clearance for a Krabbe gene therapy candidate that combines bone marrow transplant and gene therapy.
−Removed: There is some evidence that human stem cell transplant is beneficial for pre-symptomatic infants with Krabbe disease.
−Removed: There is some evidence that hematopoetic stem cell transplant is beneficial for pre-symptomatic infants with Krabbe disease, and it has become standard of care in many sites in the US.
+Added: We consider our most direct competitor with respect to PBKR03 to be Forge Biologics Inc., which has an active clinical trial evaluating a Krabbe gene therapy candidate that combines bone marrow transplant and gene therapy.
+Added: In addition, Neurogene Inc.
+Added: has a gene therapy in pre-clinical development for Krabbe.
We are also aware of other therapeutic approaches in preclinical development and an ongoing natural history study being conducted by the Children’s Hospital of Pittsburgh and certain academic studies for Krabbe disease.
6 unchanged sentences
University of Pennsylvania
−Removed: In May 2020, we entered into an amended and restated research, collaboration and licensing agreement, or the Penn Agreement, with The Trustees of the University of Pennsylvania, or Penn, for research and development collaborations and exclusive license rights to patents for certain products and technologies, which superseded the sponsored research, collaboration and licensing agreement we entered into with Penn in September 2018.
−Removed: Under the Penn Agreement, Penn granted us an exclusive, worldwide license, with the right to sublicense, under certain patent rights controlled by Penn (i) as of the effective date or (ii) arising out of the conduct of research funded by us, in each case to develop and commercialize licensed products for specific rare monogenic central nervous system, or CNS, indications.
−Removed: Penn also granted us a non-exclusive, worldwide license, with the right to sublicense in connection with the foregoing patent rights or a licensed product, under certain Penn know-how and materials
−Removed: necessary or reasonably useful to develop and commercialize such licensed products.
−Removed: The Penn license grant covers up to 17 specific rare monogenic CNS indications.
−Removed: Programs for the indications must be selected by May 2025.
−Removed: In addition, upon written notification by us and provided Penn has the right to do so, the Penn license grant automatically includes:
−Removed: (i) one or more additional indication(s) that may be treatable by the same licensed product if such indications are in the rare monogenic CNS field, and (ii) provided certain conditions are met, one or more additional indication(s) outside the rare monogenic CNS field for a specific licensed product.
−Removed: As part of our collaboration with Penn, we also agreed to fund certain research in the laboratory of Dr.
−Removed: James Wilson, or the Wilson Laboratory, relating to preclinical development of selected product candidates, with the goal of identifying and preclinically developing up to 17 product candidates for further clinical development and commercialization by us.
−Removed: We are also obligated to pay $5.0 million per year to fund discovery research in the Wilson Laboratory through May 2025.
−Removed: Our initial collaboration was for five rare monogenic CNS indications with options for seven additional rare monogenic CNS indications.
−Removed: Following the amendment in May 2020, and subsequent to our recent option exercise, our collaboration includes seven active programs for rare monogenic CNS indications and we have the option, until May 2025, to collaborate with Penn and the Wilson Laboratory on up to ten additional rare monogenic CNS indications, in each case upon payment of an option fee in the low seven figures.
−Removed: Further, through May 2025, Penn has agreed to notify us of any new technologies discovered, developed or engineered by the Wilson Laboratory as part of its discovery program, such as novel capsids, toxicity reduction technologies and delivery and formulation.
−Removed: We may add intellectual property covering any such new technology to the Penn license grant for any given indication that is within the collaboration.
−Removed: In addition, Penn will notify us of any patented manufacturing methods developed by the Wilson Laboratory during the specified research term, and we have the option to obtain a non-exclusive license under those patent rights controlled by Penn for our licensed products.
−Removed: On an indication-by-indication basis, Penn has agreed to ensure that the Wilson Laboratory will not collaborate with any commercial third party to develop another gene therapy product for the same indication during, or for one year following, its work for us on a given indication and licensed product.
+Added: We have a research, collaboration and licensing agreement, as amended, or the Penn Agreement, with Penn, for research and development collaborations and exclusive license rights to patents for certain products and technologies.
+Added: Under the Penn Agreement, we have the obligation to fund certain research relating to the preclinical development of selected rare, monogenic products in research programs as well as the new exploratory research program in non-rare and/or non-monogenic, or large, CNS indications, initially AD and TLE.
+Added: We also fund discovery research conducted by Penn through August 2026, and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements.
+Added: Our discovery research funding commitment is $5.0 million annually, paid in quarterly increments of $1.3 million through June 30, 2026.
+Added: Under the Penn Agreement, we have eight remaining options available to us to commence additional licensed programs for CNS indications until May 2026.
+Added: If we were to exercise any of these remaining options, we would owe Penn a non-refundable upfront fee of $1.0 million, with $0.5 million per product indication paid immediately and another $0.5 million fee owed upon achievement of a further developmental milestone.
+Added: The Penn Agreement requires that we make payments of up to (i) $16.5 million per product candidate for rare, monogenic disorders in the aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications.
+Added: Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications.
+Added: In addition, on a product-by-product basis, we are obligated to make up to $55.0 million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds.
+Added: Upon successful commercialization of a product using the licensed technology, we are obligated to pay to Penn, on a licensed-product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product.
+Added: In addition, we are obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement.
+Added: The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii) the expiration of the royalty period.
+Added: At any time after August 2026, we may terminate the agreement in its entirety, or for a licensed product, for convenience upon 90 days’ prior written notice to Penn.
+Added: Penn may terminate the agreement on an indication-by-indication basis if we fail to meet any diligence event and fail to timely cure such breach, or the
+Added: agreement in its entirety if we fail to pay the research funding, fail to comply with applicable laws, grant a security interest in any of the licensed patent rights, fail to achieve certain financing obligations, or make certain challenges to the licensed patent rights.
+Added: Either party may terminate the agreement for the other party’s insolvency or material breach that is not cured within a specified period of time.
+Added: We entered into an amendment, or the Amendment, to the Penn Agreement, on August 3, 2021.
+Added: Under the Amendment, we expanded the scope of the collaboration to include certain non-rare and/or non-monogenic, or large, CNS indications, initially AD and TLE and such other mutually agreed upon large CNS indications;
+Added: included an exploratory research collaboration to identify targets and early product candidates in such large CNS indications;
+Added: and extended the term to August 3, 2026 by which product candidates for CNS indications may be selected for the entire agreement.
+Added: The exploratory research program is focused on discovering targets and novel gene therapy candidates for large CNS diseases, initially focused on AD and TLE, and that can be expanded to other large CNS diseases upon mutual agreement.
+Added: The initial term of the exploratory research program is 3 years, which term can be extended by mutual agreement.
+Added: During such term we will have an exclusive right of first negotiation to include additional targets to the exploratory research program in the agreed upon large CNS indications.
+Added: Under the exploratory research program, we will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within AD and TLE (and any future large CNS indications that are mutually agreed upon) that arise from the exploratory research programs on substantially the same terms of the current Penn Agreement.
+Added: The election of any option to any such product candidates will count against our remaining eight options and will trigger the aggregate $1.0 million option fee.
+Added: As a result, we now will fund discovery research through August 3, 2026, and will now have until August 3, 2026 to exercise our remaining eight options.
+Added: We made an upfront payment of $5.0 million;
+Added: will reimburse Penn for expenses incurred in the exploratory research program;
+Added: and will pay Penn a tiered transaction fee ranging from 1-2% of the net proceeds upon certain change of control events.
+Added: Penn will notify us of any patented manufacturing methods developed by GTP during the specified research term, and we have the option to obtain a non-exclusive license under those patent rights controlled by Penn for our licensed products.
+Added: On a CNS indication-by-indication basis, Penn has agreed that GTP will not collaborate with any commercial third party to develop another gene therapy product for the same indication during, or for one year following, its work for us on a given indication and licensed product.
Under the licensed Penn patent rights, Penn retains the right to conduct (and to authorize non-commercial third parties to conduct) certain educational, research, clinical and patient care activities.
−Removed: As consideration for the licensed rights, we issued Penn 839,130 shares of our common stock in 2018.
−Removed: We also paid Penn a one-time license issuance fee of $2.5 million, and have agreed to pay Penn an annual license maintenance fee in the low six figures, which annual fee is creditable against royalties following the first commercial sale of a licensed product.
−Removed: In addition, for each licensed product, we are obligated to pay Penn up to $16.5 million in aggregate development milestone payments upon the achievement of specific development milestone events by such licensed product for a first indication, and reduced milestone payments for the second and third indications.
−Removed: We are also obligated to pay Penn, on a licensed product-by-licensed product basis, up to $55.0 million in aggregate commercial milestone payments.
−Removed: We have also agreed to pay Penn, on a licensed product-by-licensed product and country-by-country basis during the royalty period, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product.
−Removed: On a licensed product-by-licensed product and country-by-country basis, the royalty period is from the date of first commercial sale of such licensed product in a country until the latest of (i) the expiration of the last valid claim within the licensed patent rights covering such licensed product in the country in which such licensed product is made, used or sold, (ii) the expiration of the data exclusivity term conferred by the applicable regulatory authority in such country with respect to such licensed product, and (iii) the tenth anniversary of the first commercial sale of such licensed product in such country.
−Removed: In addition, we have agreed to pay Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses of our rights under the Penn Agreement.
−Removed: If we add a new program to the collaboration, the foregoing milestone, royalty and sublicensing income payments may be increased depending on when the program is added.
Under the Penn Agreement, we are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product for each of the licensed indications for prophylactic, diagnostic and therapeutic uses in humans.
−Removed: We may satisfy this obligation by achieving, for each
−Removed: licensed product, certain diligence events by a specified achievement date, which dates may be extended under certain circumstances.
+Added: We may satisfy this obligation by achieving, for each licensed product, certain diligence events by a specified achievement date, which dates may be extended under certain circumstances.
Pursuant to the agreement, Penn will be responsible for preclinical development activities, including all IND-enabling non-clinical studies and research grade manufacturing, and other collaborative activities set forth in the plan for the funded research, and we will be responsible for regulatory strategy and operations, clinical development, GMP manufacture and commercialization of all licensed products.
−Removed: The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii) the expiration of the royalty period.
−Removed: At any time after May 2025, we may terminate the agreement in its entirety, or for a licensed product, for convenience upon 90 days’ prior written notice to Penn.
−Removed: Penn may terminate the agreement on an indication-by-indication basis if we fail to meet any diligence event and fail to timely cure such breach, or the agreement in its entirety if we fail to pay the research funding, fail to comply with applicable laws, grant a security interest in any of the licensed patent rights, fail to achieve certain financing obligations, or make certain challenges to the licensed patent rights.
−Removed: Either party may terminate the agreement for the other party’s insolvency or material breach that is not cured within a specified period of time.
Intellectual Property
9 unchanged sentences
Any patents that may issue from applications in this family are expected to expire on February 27, 2038, absent any term adjustments or extensions;
−Removed: • two patent families with claims directed to an rAAV containing a coding sequence of human β-galactosidase for use in treating GM1.
−Removed: The first patent family includes a pending application in Argentina and a pending Patent Cooperation Treaty, or PCT, application.
−Removed: Based on the PCT filing, national and regional patent applications may be filed in the United States and over 150 foreign jurisdictions.
+Added: • two patent families with claims directed to an rAAV containing a coding sequence of human β-gal for use in treating GM1.
+Added: The first patent family includes pending applications in twenty-three jurisdictions, including the U.S., Argentina, Brazil, Canada, China, Europe, Israel, India, Japan, and Korea.
Any patents that may issue from applications in this family are expected to expire on September 30, 2039, absent any term adjustments or extensions.
−Removed: The second patent family includes three pending, unpublished U.S.
−Removed: provisional patent applications.
−Removed: Any patents that may issue from applications in this family are expected to expire in February 2041;
+Added: The second patent family includes applications pending in Argentina, Pakistan, and Taiwan and a pending Patent Cooperation Treaty, or PCT, application.
+Added: Based on the PCT filing, national and regional patent applications may be filed in the United States and over 150 foreign jurisdictions.
+Added: Any patents that may issue from applications in this family are expected to expire on February 1, 2041;
• two patent families with claims directed to rAAV for use in treating Krabbe.
−Removed: The first patent family includes a pending PCT application and pending applications in Argentina and Taiwan.
+Added: The first patent family includes pending applications in twenty-one jurisdictions, including the U.S., Argentina Brazil, Canada, China, Europe, Israel, India, Japan, and Korea.
Any patents that may issue from applications in this family are expected to expire on February 26, 2040, absent any term adjustments or extensions.
−Removed: The second patent family includes two pending, unpublished U.S.
−Removed: patent applications.
+Added: The second patent family includes applications pending in Argentina, Pakistan, and Taiwan and a pending PCT application.
Any patents that may issue from applications in this family are expected to expire in May 11, 2041;
• two patent families with claims directed to rAAV for use in treating FTD.
−Removed: The first patent family includes a pending PCT application and applications pending in Argentina and Taiwan.
+Added: The first patent family includes applications pending in twenty one jurisdictions, including the US, Argentina Brazil, Canada, China, Europe, Israel, India, Japan, and Korea.
Any patents that may issue from applications in this family are expected to expire on February 21, 2040, absent any term adjustments or extensions.
+Added: The second patent family includes applications in Argentina and Taiwan and a pending PCT application.
+Added: Any patents that may issue from applications in this family are expected to expire in August 2041;
+Added: • two patent families with claims directed to rAAV for use in treating MLD.
+Added: The first patent family includes applications pending in twenty four jurisdictions, including the US, Argentina Brazil, Canada, China, Europe, Israel, India, Japan, and Korea.
+Added: Any patents that may issue from applications in this family are expected to expire on May 4, 2040.
The second patent family includes one pending unpublished U.S.
provisional patent application.
−Removed: Any patents that may issue from applications in this family are expected to expire in August 2041;
−Removed: • a patent family with claims directed to rAAV for use in treating MLD.
−Removed: The patent family includes a pending PCT application and applications pending in Argentina and Taiwan.
−Removed: Any patents that may issue from applications in this family are expected to expire in May 2040, absent any term adjustments or extensions.
−Removed: • We also have options under the Penn Agreement to add additional intellectual property to our existing license, as described in the section “License Agreement.” To date, we have exercised an option with respect to Charcot-Marie Tooth disease, or CMT.
−Removed: At present, there is one patent family directed to this newly licensed indication.
−Removed: • a patent family with a pending, unpublished, U.S.
−Removed: provisional patent application directed to rAAV for use in treating CMT.
−Removed: Any patents that may issue from applications in this family are expected to expire in July 2041, absent any term adjustments and extensions.
+Added: Any patents that may issue from applications in this family are expected to expire in January 2043, absent any term adjustments or extensions ;
+Added: • one patent family with claims directed to rAAV for use in treating ALS.
+Added: The patent family includes one pending unpublished U.S.
+Added: provisional patent application.
+Added: Any patents that may issue from applications in this family are expected to expire in January 2043, absent any term adjustments or extensions.
+Added: We also have options under the Penn Agreement to add additional intellectual property to our existing license, as described in the section “License Agreement”.
+Added: To date, we have exercised an option with respect to Charcot-Marie Tooth disease, or CMT, Canavan disease, Parkinson’s disease, and Huntington’s disease .
+Added: At present, there are two patent families directed to these newly licensed indications:
+Added: • two patent families with claims directed to rAAV for use in treating CMT.
+Added: The first patent family includes a pending PCT application and applications pending in Argentina and Taiwan.
+Added: Any patents that may issue from applications in this family are expected to expire in July 13, 2041, absent any term
+Added: adjustments and extensions.
+Added: The second patent family includes two pending unpublished U.S.
+Added: provisional patent applications.
+Added: Any patents that may issue from applications in this family are expected to expire in September 2042.
The term of individual patents may vary based on the countries in which they are obtained.
13 unchanged sentences
Government Regulation and Product Approval
−Removed: Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality
−Removed: control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products.
+Added: Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products.
The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.
6 unchanged sentences
Failure to comply with applicable U.S.
−Removed: requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.
+Added: requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs,
+Added: warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.
Biological product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought.
1 unchanged sentence
Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product.
−Removed: The conduct of the preclinical
−Removed: tests must comply with federal regulations and requirements, including Good Laboratory Practices.
+Added: The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory Practices.
The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol.
2 unchanged sentences
If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.
−Removed: Clinical trials involve the administration of the investigational biologic to healthy volunteers or patients under the supervision of a qualified investigator.
+Added: Clinical trials involve the administration of the investigational biologic to subjects, including healthy volunteers or patients under the supervision of a qualified investigator.
Clinical trials must be conducted:
3 unchanged sentences
Each protocol involving testing on U.S.
−Removed: patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.
−Removed: The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial patients.
−Removed: The trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or IRB, for approval.
−Removed: An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements, or may impose other conditions if it believes that the patients are subject to unacceptable risk.
+Added: subjects and subsequent protocol amendments must be submitted to the FDA as part of the IND.
+Added: The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial subjects.
+Added: The trial protocol and informed consent information for subjects in clinical trials must also be submitted to an institutional review board, or IRB, for approval.
+Added: An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements, or may impose other conditions if it believes that the subjects are subject to unacceptable risk.
Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap.
−Removed: In Phase 1, the initial introduction of the biologic into patients, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible.
+Added: In Phase 1, the initial introduction of the biologic into subjects, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible.
Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug or biologic for a particular indication, determine optimal dose and regimen, and to identify common adverse effects and safety risks.
1 unchanged sentence
In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of the drug or biologic.
−Removed: In rare instances, including instances of gene therapies intended for rare diseases, a single Phase 3 trial with other confirmatory evidence may be sufficient where there is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.
+Added: In rare instances, including instances of gene therapies intended for rare diseases, a single Phase 3 trial may be sufficient when either (1) the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) the single trial is supported by other confirmatory evidence.
In addition, the manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug.
18 unchanged sentences
Additionally, the FDA will inspect the facility or the facilities at which the biologic product is manufactured.
−Removed: The FDA will not approve the product unless compliance with cGMP is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe, pure, potent and effective in the claimed indication.
+Added: The FDA will not approve the product unless compliance with cGMPs is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe, pure, potent and effective in the claimed indication.
After the FDA evaluates the BLA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a complete response letter.
A complete response letter generally outlines the deficiencies in the BLA submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application for approval.
−Removed: If, or when, those deficiencies have been addressed to the FDA’s
−Removed: satisfaction in a resubmission of the BLA, the FDA will issue an approval letter.
+Added: If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter.
The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included.
15 unchanged sentences
and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high.
−Removed: For instance, FDA usually recommends that sponsors observe all surviving subjects who receive treatment using gene therapies that are based on adeno-associated virus vectors in clinical trials for potential gene therapy-related delayed adverse events for a minimum 5-year period, followed by 10 years of annual queries, either in person or by questionnaire.
+Added: For instance, FDA usually recommends that sponsors observe all surviving subjects who receive treatment using gene therapies that are based on adeno-associated virus vectors in clinical trials for potential gene therapy-related delayed adverse events for a minimum 5-year period.
FDA does not require the long-term tracking to be complete prior to its review of the BLA.
6 unchanged sentences
For large molecule drugs, including gene therapies, sameness is determined based on the principal molecular structural features of a product.
−Removed: As applied to gene therapies, the FDA has recently issued draft guidance in which it stated it would consider certain key features, such as the transgenes expressed by the gene therapy and the vectors used to deliver the transgene, to be principal molecular structural features.
−Removed: With regard to vectors, the FDA intends to consider whether two vectors from the same viral class are the same or different on a case-by-case basis.
+Added: As applied to gene therapies, the FDA has recently issued final guidance in which it stated it generally intends to consider certain key features, such as the transgenes expressed by the gene therapy and the vectors used to deliver the transgene, to be principal molecular structural features.
+Added: With regard to vectors, the FDA generally intends to consider whether two vectors from the same viral class are the same or different on a case-by-case basis.
The FDA does not intend to consider minor differences between transgenes and vectors to be different principal molecular structural features.
−Removed: The FDA also intends to consider whether additional features of the final gene therapy product, such as regulatory elements and the cell type that is transduced (for genetically modified cells), should also be considered to be principal molecular structural features.
−Removed: During the seven-year marketing exclusivity period, the FDA may not approve any other applications to market a biological product containing the same principal molecular structural features for the same indication,
−Removed: except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity.
+Added: When two gene therapy products express the same transgene and have or use the same vector, determining whether two gene therapies are the same drug may also depend on additional features of the final gene therapy product, such as regulatory elements and the cell type that is transduced (for genetically modified cells).
+Added: In such cases, the FDA generally intends to determine whether two gene therapy products are different on a case-by-case basis.
+Added: During the seven-year marketing exclusivity period, the FDA may not approve any other applications to market a biological product containing the same principal molecular structural features for the same indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity.
A product can be considered clinically superior if it is safer, more effective or makes a major contribution to patient care.
2 unchanged sentences
Rare Pediatric Disease Priority Review Voucher Program
−Removed: Under the Rare Pediatric Disease Priority Review Voucher program, FDA may award a priority review voucher to the sponsor of an approved marketing application for a product that treats or prevents a rare pediatric disease.
+Added: Under the Rare Pediatric Disease Priority Review Voucher program, the FDA may award a priority review voucher to the sponsor of an approved marketing application for a product that treats or prevents a rare pediatric disease.
The voucher entitles the sponsor to priority review of one subsequent marketing application.
4 unchanged sentences
the NDA or BLA must not seek approval for a different adult indication (i.e., for a different disease/condition);
−Removed: the product must not contain an active ingredient that has been previously approved by FDA;
−Removed: and the NDA or BLA must rely on clinical data derived from studies examining a pediatric population such that the approved product can be adequately labeled for the pediatric population.
−Removed: Before NDA or BLA approval, FDA may designate a product in development as a product for a rare pediatric disease.
−Removed: To receive a rare pediatric disease priority review voucher, a sponsor must notify FDA, upon submission of the NDA or BLA, of its intent to request a voucher.
−Removed: If FDA determines that the NDA or BLA is a rare pediatric disease product application, and if the NDA or BLA is approved, FDA will award the sponsor of the NDA or BLA a voucher upon approval of the NDA or BLA.
−Removed: FDA may revoke a rare pediatric disease priority review voucher if the product for which it was awarded is not marketed in the U.S.
+Added: the product must not contain an active ingredient that has been previously approved by the FDA;
+Added: and the NDA or BLA must rely on clinical data derived from studies examining a pediatric
+Added: population such that the approved product can be adequately labeled for the pediatric population.
+Added: Before NDA or BLA approval, the FDA may designate a product in development as a product for a rare pediatric disease.
+Added: To receive a rare pediatric disease priority review voucher, a sponsor must notify the FDA, upon submission of the NDA or BLA, of its intent to request a voucher.
+Added: If the FDA determines that the NDA or BLA is a rare pediatric disease product application, and if the NDA or BLA is approved, the FDA will award the sponsor of the NDA or BLA a voucher upon approval of the NDA or BLA.
+Added: The FDA may revoke a rare pediatric disease priority review voucher if the product for which it was awarded is not marketed in the U.S.
within 365 days of the product’s approval.
The voucher, which is transferable to another sponsor, may be submitted with a subsequent NDA or BLA and entitles the holder to priority review of the accompanying NDA or BLA.
−Removed: The sponsor submitting the priority review voucher must notify FDA of its intent to submit the voucher with the NDA or BLA at least 90 days prior to submission of the NDA or BLA and must pay a priority review user fee in addition to any other required user fee.
−Removed: FDA must take action on an NDA or BLA under priority review within six months of receipt of the NDA or BLA.
+Added: The sponsor submitting the priority review voucher must notify the FDA of its intent to submit the voucher with the NDA or BLA at least 90 days prior to submission of the NDA or BLA and must pay a priority review user fee in addition to any other required user fee.
+Added: The FDA must take action on an NDA or BLA under priority review within six months of receipt of the NDA or BLA.
On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher program was reauthorized as part of the Consolidated Appropriations Act, 2021 allowing a product that is designated as a product for a rare pediatric disease prior to September 30, 2024 to be eligible to receive a rare pediatric disease priority review voucher upon approval of a qualifying NDA or BLA prior to September 30, 2026.
1 unchanged sentence
Fast Track Designation and Priority Review
−Removed: FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition.
+Added: The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition.
Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition.
Fast track designation applies to both the product and the specific indication for which it is being studied.
−Removed: Any product submitted to FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review.
+Added: Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review.
Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.
−Removed: FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.
+Added: The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.
Breakthrough Therapy Designation
5 unchanged sentences
Similar to Breakthrough Therapy designation, the RMAT allows companies developing regenerative medicine therapies to work earlier, more closely, and frequently with the FDA, and RMAT-designated products may be eligible for priority review and accelerated approval.
−Removed: Regenerative medicine therapies include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except for those regulated solely under section 361 of the PHS Act and Title 21 of the Code of Federal Regulations Part 1271.
+Added: Regenerative medicine therapies include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except for those regulated solely under section 361 of the PHS Act and Title 21 of the Code
+Added: of Federal Regulations Part 1271.
The FDA confirmed that gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy.
10 unchanged sentences
The FDA may grant full or partial waivers, or deferrals, for submission of data.
−Removed: Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer that is subject to an NDA or BLA submitted on or after August 18, 2020.
+Added: Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer.
Additional Controls for Biologics
10 unchanged sentences
Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element.
−Removed: A biosimilar product may be deemed interchangeable with a previously approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.
−Removed: To date a handful of biosimilar products and no interchangeable products have been approved under the BPCIA.
−Removed: Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to biosimilar product implementation, which is still being evaluated by the FDA.
+Added: A biosimilar product may be deemed
+Added: interchangeable with a previously approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.
+Added: The first biosimilar product was approved by the FDA in 2015, and the first interchangeable product was approved in 2021.
A reference biologic is granted 12 years of exclusivity from the time of first licensure, or BLA approval, of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product.
4 unchanged sentences
Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.
−Removed: Adverse event reporting and submission of periodic safety summary reports is required following FDA approval of a BLA.
+Added: Adverse event reporting and submission of periodic safety summary reports are required following FDA approval of a BLA.
The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product.
2 unchanged sentences
Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product’s manufacturing facilities to assess compliance with cGMPs.
−Removed: manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs.
+Added: Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs.
Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.
4 unchanged sentences
Attorney offices within the DOJ, and state and local governments.
−Removed: For example, sales, marketing and scientific/ educational grant programs, may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable.
+Added: The laws biotechnology companies may have to comply with include the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable.
The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, recommending or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs.
The term remuneration has been interpreted broadly to include anything of value.
−Removed: The Anti- Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and/or formulary managers on the other.
+Added: The Anti- Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and
+Added: prescribers, purchasers, and/or formulary managers on the other.
There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution.
19 unchanged sentences
Among other things, HITECH made HIPAA’s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity.
−Removed: HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions.
+Added: HITECH also created four new tiers of civil
+Added: monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions.
In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
−Removed: Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.
−Removed: Beginning in 2022, applicable manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse midwives during the previous year.
+Added: Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced practice nurses, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.
Commercial distribution of products requires compliance with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state.
29 unchanged sentences
Healthcare Reform
−Removed: In March 2010, President Obama enacted the ACA, which has begun to substantially change healthcare financing and delivery by both governmental and private insurers, and has also begun to significantly impact the pharmaceutical and biotechnology industry.
−Removed: The ACA will impact existing government healthcare programs and will result in the development of new programs.
−Removed: Among the ACA provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:
−Removed: • an annual, nondeductible fee on any entity that manufacturers or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs, that began in 2011;
−Removed: • an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the Average Manufacturer Price, or AMP for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the AMP;
−Removed: • a Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient drugs to be covered under Medicare Part D;
−Removed: • extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
−Removed: • expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals beginning in 2014 and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
−Removed: • expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
−Removed: • a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.
−Removed: There remain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA.
−Removed: Since January 2017, President Trump has signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA.
−Removed: Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA.
−Removed: While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, effective January 1, 2019, for not complying with the ACA’s individual mandate to carry health insurance, and eliminating the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D.
−Removed: On December 14, 2018, a Texas U.S.
−Removed: District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017.
−Removed: On December 18, 2019, the U.S.
−Removed: Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well.
−Removed: On November 10, 2020, the United States Supreme Court heard oral arguments but it is unclear when a decision will be made.
−Removed: There has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics.
−Removed: Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.
−Removed: For example, on July 24, 2020 and September 13, 2020, President Trump announced several executive orders related to prescription drug pricing that seek to implement several of the administration’s proposals.
−Removed: As a result, the FDA also released a final rule on September 24, 2020 providing guidance for states to build and submit importation plans for drugs from Canada.
−Removed: Further, on November 20, 2020, the U.S Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law.
−Removed: The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
−Removed: also published an interim final rule that establishes a Most Favored Nation, or MFN, Model for Medicare Part B drug payment.
−Removed: This regulation would substantially change the drug reimbursement landscape as it bases Medicare Part B payment for 50 selected drugs on prices in foreign countries instead of average sales price, or ASP.
−Removed: The MFN drug payment amount is expected to be lower than the current ASP-based payment limit because U.S.
−Removed: drug prices are generally the highest in the world.
−Removed: Although the MFN Model payment methodology was scheduled to begin on January 1, 2021, it faces uncertain prospects for implementation.
−Removed: By the end of December 2020, three federal courts had granted orders preventing implementation of the rule.
−Removed: In addition to these lawsuits, the change in administration or additional litigation challenging the regulation could delay or halt its implementation.
−Removed: The likelihood of implementation of any of these and the other Trump administration reform initiatives is uncertain, particularly in light of the recent change in administration on January 20, 2021.
−Removed: At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
−Removed: Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors.
−Removed: The implementation of cost containment measures or other healthcare reforms may prevent the generation revenue, attainment profitability, or commercialization of products.
−Removed: We cannot predict what healthcare reform initiatives may be adopted in the future, particularly in light of the recent presidential election.
−Removed: However, it is possible that there will be further legislation or regulation that could harm the business, financial condition and results of operations.
−Removed: Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.
+Added: Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S.
+Added: government rebate programs and additional downward pressure on pharmaceutical product prices.
+Added: On September 9, 2021, the Biden administration published a wide-ranging list of policy proposals, most of which would need to be carried out by Congress, to reduce drug prices and drug payment.
+Added: The HHS plan includes, among other reform measures, proposals to lower prescription drug prices, including allowing Medicare to negotiate prices and disincentivizing price increases, and to support market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase price transparency.
+Added: Many similar proposals, including the plans to give Medicare Part D authority to negotiate drug prices, require drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation, and cap out-of-pocket costs, have already been included in policy statements and legislation currently being considered by Congress.
+Added: It is unclear to what extent these and other statutory, regulatory, and administrative initiatives will be enacted and implemented.
Employees and Human Capital Resources
7 unchanged sentences
The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.
−Removed: Our principal executive office is located in Philadelphia, Pennsylvania, where we lease a total of 8,887 square feet of office and laboratory space that we use for our administrative, research and development and other activities.
−Removed: In April 2020, we entered into a lease agreement for new principal executive offices, which we expect to commence in March 2021, and amended our existing lease to terminate upon commencement of the new lease.
−Removed: The new premises will include approximately 37,000 square feet in Philadelphia, Pennsylvania.
−Removed: The new lease is expected to expire in January 2031, subject to our option to extend the new lease by up to two additional five-year terms.
+Added: Our principal executive office is located in Philadelphia, Pennsylvania, where we lease a total of approximately 37,000 square feet of office space, which commenced in February 2021 and will expire in December 2031, subject to our option to extend the term of the lease by up to two additional five-year terms .
We also lease approximately 62,000 square feet of laboratory space at the Princeton West Innovation Campus in Hopewell, New Jersey.
−Removed: This lease has a 15-year term from the later of (i) March 15, 2021 or (ii) the date the landlord delivers the property in sufficient delivery condition.
+Added: This lease has a 15-year term from the lease commencement date of March 2021.
We have the option to extend the term of the lease by up to two additional five-year terms.
14 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.